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Bacteria exhibit common virulence targets which can be inhibited for potential 
broad-spectrum activity across a range of bacterial infections. The macrophage 
infectivity potentiator (Mip) is a bacterial protein that has peptidylprolyl cis/trans 
isomerase activity and is part of the FK506-binding protein subgroup, in the superfamily 
of immunophilins. They have previously been identified to be involved in intracellular 
virulence of Legionella pneumophila and Burkholderia pseudomallei and inhibition of the 
protein with pipecolic acid derived small-molecule inhibitors resulted in a decrease in 
virulence. Due to the highly conserved nature of Mip proteins it is believed that these 
proteins exist in Klebsiella pneumoniae and Burkholderia cenocepacia; two pathogens 
contributing to a rise in multi-drug resistant infections. Therefore, this study aims to 
examine the potential broad-spectrum activity of the Mip inhibitors in K. pneumoniae 
and B. cenocepacia by developing in vitro model methods for inhibitor evaluation. 
The presence of putative Mip proteins in K. pneumoniae and B. cenocepacia were 
confirmed with the use of online bioinformatics tools. The Mip inhibitors were then 
examined by first developing in vitro cell based methods to identify the magnitude at 
which K. pneumoniae and B. cenocepacia adhered to macrophages, and internalised, 
survived and replicated within the macrophages. An optimised adherence assay, and 
internalisation, survival and replication assay were then used to test the efficacy of the 
Mip inhibitors in K. pneumoniae and B. cenocepacia.  
The results obtained demonstrated that K. pneumoniae and B. cenocepacia were 
able to adhere to the macrophages, however, the concentration at which they adhered 
varied between strains. Only two strains of K. pneumoniae were internalised into the 
macrophages and only one strain was able to replicate at low concentrations within the 
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macrophages during the 24 hours post-infection. All strains of B. cenocepacia were 
internalised into the macrophages, however, only one strain suggested replication 
within the macrophages during the 24 hours post-infection. The Mip inhibitors had little 
effect on adherence of K. pneumoniae to macrophages, however, trends in the data 
suggested that the Mip inhibitors had an effect on the intracellular virulence of K. 
pneumoniae and B. cenocepacia. Therefore from this preliminary study, it seems that 
Mip inhibitors have potential broad-spectrum activity in intracellular virulence of these 
pathogens. These findings provide insight into Mip proteins in K. pneumoniae and B. 
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1.1 The genus Klebsiella 
The genus Klebsiella is part of the Enterobacteriaceae family and was named after 
the German microbiologist Edwin Klebs in 1885 to honour his work (Brisse, Grimont & 
Grimont 2006). Klebsiella are facultative anaerobic, encapsulated, non-motile, Gram-
negative bacilli that have variable fermentative and biochemical activities based on the 
species (Chapman 1946). They are isolated from human respiratory, gastrointestinal and 
urinary tracts but are also widely seen in the environment (Chapman 1946). In the genus 
Klebsiella, Klebsiella pneumoniae and Klebsiella oxytoca are the most medically 
important species causing opportunistic infections in humans (Hidron et al. 2008). K. 
pneumoniae is of particular interest due to an increase in multi-drug resistant (MDR) 
strains and hospital cases. 
1.1.1 Klebsiella pneumoniae  
K. pneumoniae was first described in 1882 by Carl Friedländer who found the 
bacterium in the lungs of a patient that died of pneumonia (Brisse, Grimont & Grimont 
2006). Prior to this, two other species were also described; Klebsiella rhinoscleromatis 
and Klebsiella ozaenae. Due to the inability to distinguish between these three species 
based on DNA relatedness, they were collectively placed as subspecies under the type 
species K. pneumoniae (Brisse, Grimont & Grimont 2006). For the remainder of this 
thesis K. pneumoniae will be referring to the species K. pneumoniae subspecies 
pneumoniae. 
Clinical isolates of K. pneumoniae have an optimum growth temperature of 35 - 37 
°C on common laboratory media such as Luria-Bertani (LB) media, blood agar plates and 
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tryptic soy media. K. pneumoniae produce white, glistening, convex and smooth mucoid 
colonies on agar plates due to a polysaccharide capsule (Breed, Murray & Smith 1957; 
Ristuccia & Cunha 1984). They are rod shaped with rounded ends, measuring 0.3 – 0.5 
by 5.0 μm (Breed, Murray & Smith 1957). K. pneumoniae are capable of fermenting 
lactose and can utilise citrate as their sole carbon source (Ristuccia & Cunha 1984). They 
are also capable of using ammonia as their sole nitrogen source, converting nitrates into 
nitrites (Breed, Murray & Smith 1957).  
Like all Gram-negative bacteria, K. pneumoniae has a complex bi-layered cell wall 
(Wojciechowski 2006). The inner component of the cell wall is made up of polymer 
peptidoglycan molecules; a composite of long strands of glycan and crosslinked 
stretchable peptides (Huang et al. 2008). The outer component of the cell wall is made 
up of lipopolysaccharide molecules and has toxic activity which is responsible for many 
symptoms associated with Gram-negative infections (Wojciechowski 2006). K. 
pneumoniae also contain pili (fimbriae) on the outer membrane of the cell wall which 
assists the bacteria in adhering to cells and aids colonisation in the host (Fader, Avots-
Avotins & Davis 1979). 
The most common way to classify K. pneumoniae is by using the capsular K-antigen 
serotyping method (Brisse, Grimont & Grimont 2006). The first two capsular serotypes 
identified were by Julianelle (1926) who looked at various serological tests such as 
agglutination and precipitin reactions in different K. pneumoniae strains. Since his 
pioneering ground work, 82 capsules (K1 – K82) have been identified. However in 1977, 
5 capsular serotypes were deleted which include K73 and K75 – K78 (Ørskov & Fife-
Asbury 1977). 77 capsular serotypes remain and are part of the international K-typing 
scheme (Ørskov & Fife-Asbury 1977). 
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1.1.1.1 Disease and clinical presentation 
K. pneumoniae can cause severe and sometimes fatal infections. These include liver 
abscesses, pneumonia, urinary tract infections and septicaemia (Ristuccia & Cunha 
1984). MDR K. pneumoniae infections have been associated with adverse clinical 
outcomes, increased mortality and prolonged hospitalisation (Pons et al. 2015). The 
capsular type of K. pneumoniae is related to the severity of infection (Cortés et al. 2002; 
Mizuta et al. 1983). K1 and K2 capsular K. pneumoniae are the most commonly isolated 
strains from patients (Fang et al. 2007). A new and emerging hypervirulent 
(hypermucoviscous) phenotype of K. pneumoniae that was first identified in the mid 
1980’s has been reported to cause serious and life-threatening invasive infections (Liu, 
Cheng & Lin 1986). A devastating characteristic of this phenotype is the ability to cause 
secondary complications by spreading from the site of infection to distant parts of the 
body via unknown mechanisms (Liu, Cheng & Lin 1986). 
Clinical presentations associated with K. pneumoniae infections in pneumonic 
patients include the sudden appearance of cough, fever, rigors and pleuritic chest pain, 
shallow respiration, as well as thick, bloody sputum due to the necrotising inflammatory 
process caused by the bacteria (Prince et al. 1997; Sheff 2000). Urinary tract infections 
cause frequent urination, burning sensation and blood or pus in the urine (Sheff 2000). 
Recurrent urinary tract infections can damage renal function and even after the first 
episode of infection, renal scarring is seen in up to 57% of cases (Lin et al. 2014). 
Pyogenic liver abscesses present non-specific symptoms such as fever, fatigue, nausea 
and anorexia (Casella et al. 2009; Pope et al. 2011). Hypervirulent K. pneumoniae strains 
are capable of causing severe invasive liver abscesses with extrahepatic complications, 
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including central nervous system involvement, necrotising fasciitis, meningitis and 
endophthalmitis (Siu et al. 2012).  
Infections caused by K. pneumoniae are seen in both community-acquired settings 
and nosocomial settings, and are typically observed in patients who are 
immunocompromised. Risk factors associated with community-acquired infection 
include alcoholism, diabetes, biliary disease, cancer, acute renal failure and heart 
disorders (Jong et al. 1995; Thomsen, Jepsen & Sørensen 2007; Falagas et al. 2007). Risk 
factors associated with nosocomial K. pneumoniae infections include invasive surgery, 
burn wounds, catheters, mechanical ventilation, antimicrobial therapy, extremes of age 
and duration of stay at the hospital (Ulu et al. 2015; Brisse, Grimont & Grimont 2006). 
Vardakas et al. (2015) found that mortality rates increased with prolonged stay in the 
intensive care unit (ICU). Paediatric wards are of particular risk especially premature 
infants in ICU’s (Podschun & Ullmann 1998). 
1.1.1.2 Treatment and vaccine development 
Treatment for K. pneumoniae infections are based on whether the strain exhibits 
antibiotic resistance or not. Strains which are not MDR can be treated with 
aminoglycosides and quinolones (Wojciechowski 2006). Extended spectrum β-
lactamase (ESBL) K. pneumoniae strains can be treated with carbapenem antibiotics. 
However, in the case of K. pneumoniae carbapenemase (KPC) strains, combination 
therapy of colistin with either tigecycline or imipenem may be needed for possible 
synergistic effects as last resort drug treatments (Ah, Kim & Lee 2014; Katsiari et al. 
2015; Munoz-Price et al. 2013). 
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Vaccine efforts have continued over the past decade. The first antibody 
preparations were against the capsular polysaccharide using inactivated whole cells, 
ribosomal preparations and cell surface preparations (Riottot, Fournier & Pillot 1979; 
Fournier et al. 1981). Cryz, Fürer & Germanier (1984) found that anti-polysaccharide 
antibodies produced against a highly purified antigen provided high levels of protection 
from fatal K. pneumoniae burn wound sepsis. A human trial of this vaccine found that it 
was safe and immunogenic (Cryz, Fürer & Germanier 1985). Other vaccine efforts 
include active immunisation via whole cell vaccines, killed/attenuated vaccines, protein 
based vaccines, ribosomal vaccines and conjugate vaccines (Ahmad et al. 2012a). No 
vaccine that achieves complete protection has been discovered, however, the conjugate 
vaccine covers more than 85% of tested clinical K. pneumoniae isolates and appears safe 
for maternal use (Ahmad et al. 2012b). 
1.1.1.2.1 Antibiotic resistance  
K. pneumoniae is naturally resistant to aminopenicillins and carboxypenicillins as it 
produces a potent β-lactamase (SHV-1) which inactivates the antibiotic (Brisse, Grimont 
& Grimont 2006). This activity can in turn be inactivated by clavulanic acid. In recent 
years a wider range of resistance to β-lactams has resulted in the use of third generation 
cephalosporins, quinolones and aminoglycosides (Brisse, Grimont & Grimont 2006). The 
emergence of ESBL K. pneumoniae strains that are also resistant to third generation 
antibiotics have increased in frequency and become a cause for concern (Breurec et al. 
2013; Yu et al. 2002; Hardy, Legeai & O’Callaghan 1980). In the case of these MDR K. 
pneumoniae pathogens, carbapenem antibiotics have been utilised as treatment 
options. However, since the first emergence of carbapenem hydrolysing enzymes in 
1993, KPC strains have continued to increase globally (Bradford et al. 1997; Ahmad et 
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al. 1999). They are able to hydrolyse penicillins, all cephalosporins, monobactams, 
carbapenems, and β-lactamase inhibitors (Papp-Wallace et al. 2010). Colistin and 
tigecycline have been reserved for last resort therapy but colistin-resistant K. 
pneumoniae strains have also been reported in surveillance studies (Ah, Kim & Lee 
2014). These highly resistant pathogens have very few antibiotic treatments left.  
1.1.1.3 Epidemiology 
Klebsiella species occur naturally and can be found in two different habitats. In the 
environment they are present in water, sewage, soil and on plants (Brisse, Grimont & 
Grimont 2006). They can also be found on the mucosal surface of humans and animals 
(Podschun & Ullmann 1998). In humans, K. pneumoniae are present as saprophytes and 
colonise the nasopharynx and intestinal tract (Podschun & Ullmann 1998). They are 
considered transient flora on human skin due to the inability to find good growth 
conditions, however, carrier rates on the skin increase dramatically in hospital settings 
(Podschun & Ullmann 1998). Colonisation rates of Klebsiella species increase in direct 
proportion to length of stay in hospitals and hospital personnel have increased Klebsiella 
carriage (Casewell & Phillips 1977).  
Studies conducted on the distribution of various serotypes among K. pneumoniae 
clinical isolates have found that K1 serotypes were mostly isolated from regions of 
similar geographical locations. This included Taiwan, China and Japan but very few in 
Europe and the United States (Fung et al. 2000). Other studies have found that in 
addition to K1 serotypes, K2 serotypes are prevalent in clinical isolates, especially 
causing community-acquired liver abscesses. (Fung et al. 2002; Liu, Wang & Jiang 2013). 
Developing countries such as South East Asia, have high numbers of community-
acquired K. pneumoniae infections due to the hypervirulent strains present in that area 
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(Siu et al. 2012). In Western countries, community-acquired infections are not as 
prevalent, however, nosocomial infections are a major problem (Brisse, Grimont & 
Grimont 2006). Since the first emergence of KPC strains, a report conducted by the 
World Health Organisation (WHO) in April 2014 found that KPC has spread to all regions 
of the world (WHO 2014). KPC is endemic in the USA, South East Asia, parts of South 





Figure 1.1 Global distribution of K. pneumoniae carbapenemase strains by 
country of origin 
KPC-2 and KPC-3 hydrolyse several different classes of β-lactams. Other 





1.1.1.4 Virulence factors  
1.1.1.4.1 Capsular polysaccharides  
K. pneumoniae possess a hydrophilic polysaccharide capsule and is classified into 
77 serological types (Figure 1.2) (Ørskov & Fife-Asbury 1977). The thick, capsule protects 
the bacteria from phagocytosis and bactericidal serum factors (Podschun, Penner & 
Ullman 1992; Williams et al. 1983). Some serotypes such as K7 contain a repetitive 
sequence of mannose-α-2/3-mannose or L-rhamnose-α-2/3-L-rhamnose which are 
recognised by a surface lectin on macrophages that mediates phagocytosis (Athamna et 
al. 1991). Macrophages with the mannose-α-2/3-mannose-specific lectin or mannose 
receptor recognise K. pneumoniae and are able to ingest and mediate phagocytosis of 
the bacteria (Ofek, Goldhar & Keisari 1995). Serotypes such as K2 which lack mannose-
α-2/3-mannose structures are not recognised by macrophages and are able to evade 
phagocytosis (Podschun & Ullmann 1998). These serotypes are mostly associated with 
invasive infectious diseases (Podschun & Ullmann 1998). When tested via 
intraperitoneal injection in mice it was found that K1 and K2 capsular types showed 
highest levels of virulence (Mizuta et al. 1983).  Hypervirulent K. pneumoniae strains are 
associated with heightened virulence due to the acquisition of the rmpA gene, which 
partly mediates the increase in capsule production (Patel, Russo & Karchmer 2014).  
1.1.1.4.2 Pili 
Type 1 pili are the most common pili found in clinical isolates of K. pneumoniae and 
are responsible for D-mannose-sensitive haemagglutination. They are associated with 
virulence as they facilitate binding of bacteria to mucus or epithelial cells of the urinary, 
gastrointestinal and respiratory tracts (Figure 1.2) (Ofek & Beachey 1978; Venegas et al. 
1995). Studies conducted in Escherichia coli have found that type 1 pili can also bind to 
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mannosyl-containing glycoproteins in the urine and saliva, providing an explanation to 
colonisation of bacteria in the urinary and respiratory tracts (Reinhart, Obedeanu & 
Sobel 1990; Babu et al. 1986). When in the host tissue, type 1 pili are no longer of use 
to the bacteria as they trigger phagocytosis and intracellular killing of the bacteria. To 
counteract this host defence, expression of type 1 pili may be switched off (Brisse, 
Grimont & Grimont 2006).  
Type 3 pili are referred to as “mannose-resistant Klebsiella-like heamagglutination” 
and were first identified in Klebsiella strains (Clegg & Gerlach 1987). They are 
characterised by their ability to agglutinate erythrocytes treated with tannic acid in vitro 
(Duguid 1959). Type 3 pili can adhere to endothelial and epithelial cells of the respiratory 
and urinary tracts (Hornick et al. 1992; Tarkkanen et al. 1997). In vitro studies have found 
that they play a role in biofilm formation on abiotic surfaces and thus are capable of 
biofilm mediated catheter infections in the urinary system (Di Martino et al. 2003; 
Murphy et al. 2013). Type 3 pili also bind to extracellular matrix proteins such as collagen 
and promote biofilm formation due to the exposed tissue basement membrane from 
device (e.g. catheters) associated tissue damage (Boddicker et al. 2006).  
1.1.1.4.3 Siderophores 
Iron is essential for the growth of bacteria as it mainly functions as a redox catalyst 
of oxygen and electron transport reactions (Braun 2001). Khimji and Miles (1978) found 
that when iron was administered to guinea pigs, the infection potential of Klebsiella was 
enhanced. Klebsiella species produce two iron-chelating compounds called enterobactin 
(also known as enterochelin) and aerobactin (Figure 1.2). These siderophores have high-
affinity to iron, with enterobactin being the main iron uptake system of enterobacteria 
(Brisse, Grimont & Grimont 2006). Aerobactin is not as common as enterobactin as only 
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a few strains produce the siderophore (Williams et al. 1987). However, a study 
conducted by Nassif and Sansonetti (1986) found that when the aerobactin gene was 
cloned from the plasmid of K1 and K2 K. pneumoniae isolates and transferred into a 
siderophore negative strain, a marked increase in virulence was observed. This suggests 
that aerobactin has a role in virulence but due to its lower affinity to iron in comparison 
to enterobactin, the latter is favoured (Podschun & Ullmann 1998). A study conducted 
on the secretion of siderophores in hypervirulent strains of K. pneumoniae found that 
these strains secreted a 3 to 7 fold higher concentration, in comparison to non-
hypervirulent strains (Russo et al. 2011). 
1.1.1.4.4 Serum resistance and lipopolysaccharides 
Other virulence factors associated with K. pneumoniae include serum resistance 
and lipopolysaccharides (Figure 1.2). The first-line of defence by host immunity is 
phagocytosis and the cascade-like activation of bactericidal serum which creates trans-
membranous pores in the outer membrane of Gram-negative bacteria, leading to an 
influx of sodium ions and results in lysis of the bacterial cell (Taylor & Kroll 1985; Ramm 
et al. 1983). Commensal bacteria are susceptible to this host defence but pathogenic 
Gram-negative bacteria have developed serum resistance mechanisms (Olling 1977). 
Lipopolysaccharides are composed of lipid A and a side chain called the “O-antigen”. 
There are nine O-antigens in K. pneumoniae, with O1 being the most frequent (Hansen 
et al. 1999). Lipopolysaccharides activate the cascade-like reaction of bactericidal serum 
causing phagocytosis of the bacterial cell. However, it is believed that in K. pneumoniae 
the O-antigen side chain length is important in bypassing activation of complement 
factor C3b due to steric effects of the long O chain, thus protecting the bacterium from 









Figure 1.2 Schematic diagram of K. pneumoniae virulence factors  









1.2 The genus Burkholderia 
The genus was first defined by Yabuuchi et al. (1992) who proposed that seven 
species in the genus Pseudomonas homology group II, be placed in a new genus called 
Burkholderia to honour the work of bacteriologist, Walter H. Burkholder. The genus 
Burkholderia is part of the Burkholderiaceae family and consists of over 30 species 
(Coenye & Vandamme 2003). They are motile, aerobic, Gram-negative bacilli and 
contain a cell wall like other Gram-negative bacteria (Breed, Murray & Smith 1957). 
Burkholderia species can inhabit diverse ecological niches and have been isolated from 
soil, plants, water and insects. They are also found in hospital settings, industrial 
environments and cause opportunistic infections in humans (Coenye & Vandamme 
2003). Several Burkholderia species are of medical interest due to the severe infections 
and rapid disease progression of these bacteria. Species of the Burkholderia cepacia 
complex have emerged as important pathogens in individuals with cystic fibrosis and 
chronic granulomatous disease, causing morbidity and mortality (Isles et al. 1984; 
Johnston 2001) 
1.2.1 The Burkholderia cepacia complex 
B. cepacia was first placed in the genus Pseudomonas and named Pseudomonas 
cepacia due to the bacterium’s phenotypic characteristics, which include the utilisation 
of carbon and the presence of polar flagella (Vinion-Dubiel & Goldberg 2003). B. cepacia 
was first identified by Walter H. Burkholder, who observed that the bacteria were the 
causative agent of ‘sour skin’ onion rot (Vinion-Dubiel & Goldberg 2003). Since the 
identification of phenotypically similar but genetically distinct B. cepacia isolates, the 
group has been divided into at least 17 species called the Burkholderia cepacia complex 
(Bcc) (Vandamme et al. 1997; Leitão et al. 2010).  
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Bcc bacteria are non-sporulating and are typically catalase- and oxidase positive 
(Govan, Hughes & Vandamme 1996). Three different selective media have been 
developed to isolate Bcc based on their utilisation of lactose, sucrose and their 
resistance to antibiotics such as polymyxin, gentamicin and vancomycin. These are 
Pseudomonas cepacia agar, oxidation-fermentation polymyxin bacitracin lactose agar 
and Burkholderia cepacia selective agar (Woods & Sokol 2006). Bcc bacteria can also 
grow on non-selective media such as LB media, blood agar plates and tryptic soy media 
(Miller, LiPuma & Parke 2002). On agar plates, Bcc colonies can appear matte and dry 
for some strains, and shiny, smooth and slightly raised for other strains (Chung et al. 
2003). Optimal growth temperatures are between 30 – 37°C (Govan, Hughes & 
Vandamme 1996).  
The Bcc is categorised in genomovars that are based on the genetic variances of the 
bacteria and are given a species name when a distinguishable phenotypic characteristic 
is seen (Vandamme et al. 1997; Ursing et al. 1995). Genomovar I is named as the type 
species B. cepacia and since then, many genomovars and species have been identified 
(Table 1.1). 
 
Table 1.1 Overview of the Burkholderia cepacia complex 
Species name Genomovar designation 
B. cepacia B. cepacia genomovar I 
B. multivorans B. cepacia genomovar II 
B. cenocepacia B. cepacia genomovar III 
B. stabilis B. cepacia genomovar IV 
B. vietnamiensis B. cepacia genomovar V 
B. dolosa B. cepacia genomovar VI 
B. ambifaria B. cepacia genomovar VII 
B. anthina B. cepacia genomovar VIII 
B. pyrrocinia B. cepacia genomovar IX 
 
(Coenye & Vandamme 2003) 
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Burkholderia cenocepacia (previously known as genomovar III) was named by 
Vandamme et al. (2003) and is 0.6 to 0.9 by 1.0 to 2.0 µm. Growth can be seen between 
25 - 37 °C, with growth at 42 °C being strain dependent. Certain properties of B. 
cenocepacia are also strain dependent. These include yellow pigmentation of bacterial 
colonies, urease and β-galactosidase activity, nitrate reduction and malonate utilisation 
(Vandamme et al. 2003). Oxidase and catalase activity is present as is lecithinase activity. 
1.2.1.1 Disease and clinical presentation 
Bcc bacteria are opportunistic pathogens that cause infections in 
immunocompromised individuals (Speert 2002). They infect the respiratory and urinary 
tract leading to bacteraemia, endocarditis, pneumonia, liver abscesses and septic shock 
(Mukhopadhyay, Bhargava & Ayyagari 2004; Govan, Hughes & Vandamme 1996). High 
fever and chills have also been observed in infected patients (Mukhopadhyay, Bhargava 
& Ayyagari 2004). Bcc infections most commonly occur in cystic fibrosis and chronic 
granulomatous disease patients (Speert 2002; Govan, Hughes & Vandamme 1996). 
Chronic granulomatous disease is a genetic immunodeficiency disorder of leukocyte 
function (Heyworth, Cross & Curnutte 2003). In chronic granulomatous disease, the 
oxidative function of leukocytes is disabled (Speert 2002). Bcc bacteria are resistant to 
non-oxidative means of phagocytosis and thus infections persist, causing a much higher 
risk of detrimental and possibly fatal outcome (Speert et al. 1994).  
Over the past decade, Bcc bacteria have become particularly virulent pathogens in 
cystic fibrosis patients (Speert 2002). It is believed that there is an imbalance in 
oxidant/antioxidant in cystic fibrosis lungs, enabling oxidative-killing-resistant bacteria 
to survive (Speert 2002). Co-infection with Pseudomonas aeruginosa protects Bcc 
bacteria as P. aeruginosa is able to suppress oxidative radicals, providing a niche where 
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replication in the host can occur after the establishment of chronic P. aeruginosa 
infection (Speert 2002).  
B. cenocepacia is one of the most prevalent pathogens of the Bcc in cystic fibrosis 
patients (Sajjan, Keshavjee & Forstner 2004). Symptoms include severe pulmonary 
inflammation, necrotising pneumonia and sepsis (Sajjan et al. 2008). Chronic infections 
can lead to ‘cepacia syndrome,’ a rapid deterioration in lung function characterised by 
progressive pneumonic illness, marked pyrexia and multi-organ failure (Blackburn et al. 
2004). Cystic fibrosis patients infected with Bcc bacteria can develop ‘cepacia syndrome’ 
years after first being colonised, as was seen in a case study of a boy who developed it 
nine years after first infection (Blackburn et al. 2004). The control of infection to prevent 
exacerbations is critical in avoiding ‘cepacia syndrome’ and the rapid deterioration of 
health. Risk factors associated with Bcc colonisation in patients include hospitalisation 
where contamination can occur from Bcc-positive patients via contaminated surfaces, 
patient-to-patient transmission and on the hands of health care workers, as well as in 
the environment and through social contact (Fung et al. 1998).    
1.2.1.2 Treatment 
Treatment options for Bcc bacteria are limited due to the resistance of a wide range 
of antimicrobial agents (LiPuma 2005). Current treatment options are best tackled on a 
case by case basis as no optimum treatment for pulmonary exacerbations are known 
(Horsley & Jones 2012). The use of combination therapy for synergistic effects is the best 
option with the current lack of novel antimicrobials. Common antibiotics used in 
combination include meropenem, ciprofloxacin, minocycline, trimethoprim-
sulfamethoxazole, and chloramphenicol (Zhou et al. 2007). It has been observed that 
triple combination antibiotics can have a much greater likelihood of bactericidal effects 
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against Bcc and that combinations such as meropenem, tobramycin and another agent 
were bactericidal against 81% to 93% of isolates (Aaron et al. 2000). The safety of such 
combinations is unknown as limited published reports on the treatment of Bcc in cystic 
fibrosis patients are available (Zhou et al. 2007). The end goal for treatment in Bcc 
colonised patients however is not to eradicate the infection but to control the infection 
and prevent exacerbations that increase inflammation and further deterioration of lung 
function (Aaron et al. 2000). Currently no vaccine is available. 
1.2.1.2.1 Antibiotic resistance  
Bcc bacteria are among some of the most antibiotic resistant pathogens in clinical 
laboratories being resistant to a wide range of drugs such as polymyxins, 
aminoglycosides and most β-lactams (Figure 1.3) (Drevinek & Mahenthiralingam 2010). 
They are capable of developing in vivo resistance through mechanisms of enzyme 
inactivation (β-lactamases, aminoglycoside-inactivating enzymes and dihydrofolate 
reductase), alteration of drug targets, cell wall permeability and active efflux pumps 
(Drevinek & Mahenthiralingam 2010). Bcc limit access of antibiotics to bacterial cells 
through three main mechanisms. The lipopolysaccharide found on the bacteria’s cell 
wall limits the binding of Bcc pathogens to cationic antibiotics as well as cationic 
peptides of the human innate immune system (LiPuma 2007). Porins are hydrophilic 
channels on the cell membrane that allow water soluble antibiotics into the cell. In Bcc 
bacteria these channels have been found to be impermeable to antibiotics due to low 
porin expression and/or because of changes to the porin channel inhibiting antibiotic 
uptake (Parr et al. 1987; Aronoff 1988).  
Efflux systems can modulate susceptibility to broad-spectrum antibiotics and 
specific antimicrobial compounds (Holden et al. 2009). When the epidemic ET12 lineage 
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B. cenocepacia strain was sequenced, it was found that the bacteria had six classes of 
efflux system: the major facilitator superfamily, ATP binding cassette family, small multi-
drug resistance family, resistance nodulation division (RND) family, multidrug and toxic 
compound extrusion family and the fusaric acid resistance family proteins (Holden et al. 
2009). The RND family is notably the best characterised efflux system in the sequenced 
strain and was found to confer resistance to chloramphenicol, trimethoprim and 
ciprofloxacin (Drevinek & Mahenthiralingam 2010; Nair et al. 2004). In addition to this, 
biofilm formation may contribute to antibiotic resistance by limiting drug diffusion 
through the biofilm, drug inactivation in the biofilm, the presence of less susceptible 
stationary-phase bacteria and the up-regulation of biofilm associated antibiotic 









Figure 1.3 Antibiotic resistance mechanisms of the Bcc bacteria 
Antibiotic resistance is in all compartments of the bacteria. The outer membrane 
efflux pump actively exports chloramphenicol, trimethoprim and quinolones. A 
trimethoprim-resistant dihyrodrofolate reductase (DHFR) enzyme has been 
detected in some Bcc bacteria. Porin proteins found on the outer membrane do not 
allow transport of some antibiotics into the cell. Two β-lactamase mechanisms 
inhibit β-lactam activity. Periplasmic β-lactamases degrade activity of the antibiotic 
and penicillin-binding proteins (PBP) are less susceptible to their action 











Bcc bacteria are incredibly versatile, surviving in harsh and widespread 
environments and adapting to nutritional variances (LiPuma 2005). Such environments 
include being able to adapt and survive for long periods of time in disinfectants and 
anaesthetic solutions in hospitals (Govan, Hughes & Vandamme 1996). Bcc infections 
are mostly nosocomial and are thought to cause infection in cystic fibrosis and chronic 
granulomatous disease patients via contaminated ultrasound gel, nebulised 
medications, nasal spray, hospital water, and lipid emulsion (Hutchinson et al. 2004; 
Balkhy et al. 2005; Nasser et al. 2004; Doit et al. 2004; LiPuma 2005). Community-
acquired Bcc infections are rare, although there have been reports from the 1990’s that 
have shown disturbing Bcc infections causing fatality in previously healthy individuals 
(Govan, Hughes & Vandamme 1996). 
Infections caused by specific genomovars are unanimous in the literature. It is seen 
that B. cenocepacia (genomovar III-A/III-B) followed by Burkholderia multivorans 
(genomovar II) are the most prevalent Bcc infections for cystic fibrosis sufferers. Four 
independent studies conducted in the United States of America (USA), Canada, United 
Kingdom (UK) and Italy found that B. cenocepacia was the cause of greater than 50% of 
infections in the populations studied (Table 1.2) (LiPuma et al. 2001; Speert et al. 2002; 
De Soyza et al. 2004; Agodi et al. 2001). Another study conducted in Australia during a 
10 year period found that 43.1% of the population was infected with B. cenocepacia 
(Table 1.2) (Ramsay et al. 2013). Pope, Short and Carter (2010) found that in New 
Zealand, B. multivorans was the most prevalent pathogen with 79.5% of the cystic 
fibrosis population studied being infected with the bacteria (Table 1.2). Epidemic B. 
cenocepacia strain ET12 and closely phylogenetically related strains were seen in the 
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population studies in USA, Canada, UK and Italy (LiPuma et al. 2001; Speert et al. 2002; 
De Soyza et al. 2004; Agodi et al. 2001). The Australia and New Zealand studies found a 
prevalence in the Australian epidemic B. cenocepacia strain ST39 (Ramsay et al. 2013; 
Pope, Short & Carter 2010). 
 
Table 1.2 Distribution of Bcc isolates from six cystic fibrosis population studies  
‘Other’ refers to other species/genomovars in the Bcc and indeterminate isolates.  
 Prevalence (%) 














B. cepacia 2.6 0.2 3.5 0 12.3 0.0 3.1 
B. multivorans 37.8 9.7 4.7 38 26.2 79.5 32.7 
B. cenocepacia 50.0 82.9 74.4 55 43.1 12.8 53.0 
B. stabilis 0.2 3.8 3.5 0 0 5.1 2.1 
B. vietnamiensis 5.1 1.6 0 7 4.6 2.6 3.5 
Other 4.3 1.8 13.9 0 13.8 0 5.6 
 
ˣ LiPuma et al. 2001, ˢ Speert et al. 2002, *Agodi et al. 2001, ° De Soyza et al. 2004,  
ˠ Ramsay et al. 2013, + Pope, Short & Carter 2010 
 
There have been few epidemiological studies on the prevalence of Bcc in chronic 
granulomatous disease. Greenberg et al. (2009) found that over an 11 year period, no 
epidemic strains infecting multiple patients were identified. The epidemic strains 
commonly seen in cystic fibrosis communities such as ET12 were also not observed. In 
contrast to cystic fibrosis where B. cenocepacia and B. multivorans dominate infections, 
a much broader representation of Bcc have been isolated from the chronic 
granulomatous disease study population, including Burkholderia ambifaria and 
Burkholderia metallica; pathogens that are rarely isolated from humans, including 
patients with cystic fibrosis (Greenberg et al. 2009). The reasons for differences in 
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epidemiology between cystic fibrosis and chronic granulomatous disease are not readily 
apparent however it is thought that the interaction between the pathogen and the host 
is a factor (Greenberg et al. 2009). 
1.2.1.4 Virulence factors of Burkholderia cenocepacia 
1.2.1.4.1 Quorum sensing  
Quorum sensing in B. cenocepacia allows the bacteria to communicate with one 
another and coordinate multicellular behaviour by gene regulation on the basis of 
population density (Loutet & Valvano 2010). The cepIR quorum sensing system in B. 
cenocepacia mediates the production of N-octanoylhomoserine lactone and it has been 
shown that this system is required for motility, biofilm stability and virulence in the rat 
agar model of chronic lung infection (Tomlin et al. 2005; Sokol et al. 2003; Loutet & 
Valvano 2010). B. cenocepacia has a second homoserine lactone-producing quorum 
sensing system labelled cciIR that contributes to the regulation of the same functions as 
cepIR though in reverse, suggesting that a complex network of gene regulation occurs in 
response to bacterial cell density (Malott et al. 2005; Loutet & Valvano 2010). A third 
quorum sensing system exists that can utilise non-homoserine lactone compounds such 
as cis-2-dodecenoic acid in a cell density-dependent manner (Boon et al. 2008). This 
diffusible signal has many of the same functions as cepIR and cciIR (Loutet & Valvano 
2010).  
1.2.1.4.2 Siderophores 
B. cenocepacia synthesise four siderophores during conditions of iron depletion. 
These are ornibactin, pyochelin, cepaciachelin, and cepabactin that act to scavenge free 
iron from the surrounding environment (Loutet & Valvano 2010; Drevinek & 
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Mahenthiralingam 2010). The most prominent siderophore produced by most strains of 
B. cenocepacia is ornibactin (Darling et al. 1998). Studies have shown that ornibactin is 
important in virulence of rat agar bead, G. mellonella, and C. elegans infection models 
and that iron may play a role in adherence and colonisation of the bacteria (Sokol et al. 
1999). B. cenocepacia can also use ferritin, an iron-binding protein, to serve as an 
important iron source during cystic fibrosis lung infections as ferritin is in much higher 
concentrations in cystic fibrosis patients than healthy individuals (Whitby et al. 2006).  
1.2.1.4.3 Motility and adherence  
The flagellum is important to B. cenocepacia as it allows motility and enables the 
pathogen to invade the host (Tomich et al. 2002). Drevinek et al. (2008) found that when 
B. cenocepacia was incubated in cystic fibrosis sputum, increased transcriptional flagella 
genes were detected. Retained motility may account for the pathogen’s ability to invade 
host cells and cause severe infection (Drevinek & Mahenthiralingam 2010). It has also 
been observed that the regulation of flagellar gene transcription is dependent on 
quorum sensing (O’Grady et al. 2009). Certain strains of B. cenocepacia such as ET12 
express pili (Urban et al. 2005). Cable pili are peritrichous organelles on the surface of 
the bacteria and it has been demonstrated that they are capable of adhering to mucin 
as well as human buccal, bronchial, and respiratory epithelial cells (Sajjan et al. 1992; 
Sajjan et al. 2000; Chiu et al. 2001). The expression of cable pili in combination with 
adhesion AdhA bound to cytokeratin 13 has been shown to cause optimum binding 
capabilities and transmigration into the host (Urban et al. 2005). Cytokeratin 13 is a 
protein expressed on the basal layer of tracheal and bronchial epithelial cells. When 
repeated injury and repair occurs an increase in expression is seen (Urban et al. 2005). 
This condition is especially observed in cystic fibrosis patients and allows for a suitable 
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environment for highly transmissible B. cenocepacia strains (Sajjan et al. 2000; Urban et 
al. 2005). 
Thus far the cable pili is the only adhesin which has been extensively studied in B. 
cenocepacia however, recent studies have identified the presence of trimeric 
autotransporter adhesins (TAA) (Mil-Homens & Fialho 2011). These adhesins are surface 
proteins found in Gram-negative bacteria and have been demonstrated to adhere to 
extracellular matrix proteins and host cells (Mil-Homens et al. 2014). TAAs are involved 
in biofilm formation, cell-to-cell aggregation, protecting the bacterium from host 
immune responses (serum resistance), and promoting the invasion of host cells (Heise 
& Dersch 2006; Serruto et al. 2009). 
1.2.1.4.4 Polysaccharides 
B. cenocepacia express lipopolysaccharides which are one of the main components 
of the outer surface of the bacteria (Drevinek & Mahenthiralingam 2010). The O-antigen 
contained within the lipopolysaccharide prevents phagocytosis within the host but also 
interferes with B. cenocepacia adherence to epithelial cells (Saldías, Ortego & Valvano 
2009). Some B. cenocepacia strains do not contain the O-antigen, alluding to the fact 
that the O-antigen is not particularly necessary for virulence. B. cenocepacia also 
produce exopolysaccharides that are released into the surrounding environment and 
help with biofilm formation. Exopolysaccharides give the bacteria a mucoid appearance 
and have been associated with the chronicity of infection in cystic fibrosis (Drevinek & 
Mahenthiralingam 2010). Expression of exopolysaccharide is strain specific and when 
expressed does show an increase in virulence, however, the absence of 
exopolysaccharide does not mean the strain is incapable of producing severe infection 
in the host and this should not be ruled out (Drevinek & Mahenthiralingam 2010). 
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1.3 Macrophage infectivity potentiator proteins 
The highly conserved immunophilin superfamily is a group of proteins that are 
found in plants, bacteria, fungi and vertebrates. The superfamily is divided into three 
unrelated amino acid sequence subfamilies based on the immunosuppressive 
compound they bind: FK506-binding proteins (FKBP) bind to FK506 and rapamycin, 
cyclophilins bind to cyclosporine A and parvulins bind to juglone (Göthel & Marahiel 
1999). Macrophage infectivity potentiator (Mip) proteins are microbial FKBP’s that 
exhibit peptidylprolyl cis/trans isomerase (PPIase) activity (Barik 2006).  PPIase activity 
is essential in proper protein folding as it accelerates the spontaneous isomerisation of 
the cis/trans peptidylprolyl bond (Schmid 1993). 
Mip proteins were first identified by Cianciotto et al. (1989) who found a 24-kDa 
surface protein on the bacterial species Legionella pneumophila (the causative agent of 
Legionnaires' disease), involved in the intracellular virulence of the pathogen. The 
construction of an L. pneumophila mutant which was defective in the expression of the 
24-kDa protein showed an impairment in the pathogens ability to infect U937 cells and 
human alveolar macrophages but regained infectivity when the 24-kDa gene was intact, 
suggesting that the protein is needed for full virulence of L. pneumophila (Cianciotto et 
al. 1989). Studies conducted by Fischer et al. (1992) found that the Mip protein of L. 
pneumophila had PPIase activity, and that it was inhibited by FK506 and was resistant 
to cyclosporin A; reminiscent of members in the FKBP family. Mip proteins also have 
homologous regions similar to those found in FKBP’s of eukaryotic organisms (Fischer et 
al. 1992). Thus, Mips represent a bacterial gene product of the FKBP subfamily and 
shares similar characteristics to eukaryotic proteins (Fischer et al. 1992).  
26 
 
Since the first discovery of the Mip protein in L. pneumophila, other Mip-like 
proteins have been identified in different bacteria including Chlamydia trachomatis, 
Neisseria gonorrhoeae, Burkholderia pseudomallei and the protozoan Trypanosoma 
cruzi (Lundemose, Kay & Pearce 1993; Leuzzi et al. 2005; Norville et al. 2011a; Moro et 
al. 1995).  Similar to the L. pneumophila study, Leuzzi et al. (2005) created a knockout 
strain of N. gonorrhoeae Mip protein by deleting the Mip gene. It was found that the 
Mip mutant strain had the same adherence and internalisation capabilities in 
macrophages as the wild-type strain. However a reduced survival 24 hours following 
infection was observed, suggesting that Mip proteins in N. gonorrhoeae is important in 
the persistence of the pathogen in macrophages and protecting the pathogen from 
macrophage mediated killing (Leuzzi et al. 2005). Similarly Norville et al. (2011a) 
identified a Mip protein in B. pseudomallei. Deletion of the Mip gene resulted in reduced 
intracellular survival and replication in eukaryotic cells, and attenuation in BALB/c 
mouse models of infection. The C. trachomatis Mip protein was identified by inhibiting 
the protein with rapamycin; confirming that it is part of the FKBP family (Lundemose, 
Kay & Pearce 1993). Based on the results of rapamycin inhibition, it was suggested that 
inhibiting the protein interfered with one or more early stage infective events of 
intracellular infection (Lundemose, Kay & Pearce 1993). As observed, Mip proteins are 
a virulence factor for a number of pathogenic bacteria, as interfering with this protein 
leads to a decrease in infectivity of the pathogen. Due to the highly conserved nature of 
Mips, it is believed that putative Mip proteins exist in K. pneumoniae and B. cenocepacia. 
Therefore, they have been presented as potential novel antimicrobial targets.  
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1.4 Virulence targets for novel inhibitors 
Targeting virulence factors found in a wide range of bacteria can offer potential for 
the development of novel inhibitors with broad-spectrum activity (Sarkar-Tyson & 
Atkins 2011). Targets need to be specific to bacteria with no human homologs and be 
essential for bacterial virulence (Sarkar-Tyson & Atkins 2011). Developing novel 
inhibitors to treat MDR pathogens can greatly improve prognosis, economic burden and 
healthcare among many other issues associated with difficult to treat infections. 
Decreasing the infectious potential of these pathogens with novel inhibitors can 
improve antibiotic activity in killing the bacteria and minimise the likelihood of the 
development of MDR strains. Examples of novel inhibitors include quorum sensing 
inhibitors, cell division inhibitors and Mip inhibitors. 
1.4.1 Quorum sensing inhibitors 
Interfering with the quorum sensing system and the activation of quorum sensing 
genes affects bacterial virulence. Quorum sensing inhibitors work by either inhibiting 
the signal molecules produced by bacteria or interfering with the signal receptor 
(Rasmussen & Givskov 2006). Signal molecule inhibition can be achieved through 
chemical degradation, enzymatic destruction and metabolism of the N-Acyl homoserine 
lactone molecule, whereas signal receptor interference can be achieved through the 
blockage or destruction of receptor protein (Rasmussen & Givskov 2006). Quorum 
sensing inhibitors can be synthetic in origin, however, inhibitors are found widely in 
nature. Plants, fungi and animals have co-existed with bacteria for many years and some 
produce quorum sensing inhibitors to reduce colonisation capability and competition 
(Rasmussen & Givskov 2006). An example of quorum sensing inhibition is explored by 
O’Loughlin et al. (2013) who found that the use of the compound meta-bromo-
28 
 
thiolactone inhibited the expression of the genes encoding the virulence factor 
pyocyanin, preventing biofilm formation and protected human lung cells from killing by 
P. aeruginosa; a species commonly co-infecting cystic fibrosis patients with the Bcc 
pathogens.  
1.4.2 Cell division inhibitors  
All bacterial species possess mechanisms of cell division as it is essential for 
propagation (Sarkar-Tyson & Atkins 2011). The FtsZ protein is found in almost all 
bacterial species and forms the contractile ring called the Z ring on the inner surface of 
the cytoplasmic membrane at the site of division (Buddelmeijer & Beckwith 2002). Like 
tubulin in eukaryotic cells, FtsZ has GTPase activity and forms tubulin-like protofilaments 
(Boer, Crossley & Rothfield 1992; Erickson et al. 1996). The differences between 
eukaryotic and prokaryotic tubulin has enabled exploitation to find compounds that 
inhibit bacterial tubulin and not affect host tubulin (Buddelmeijer & Beckwith 2002).  
Inhibition of the FtsZ protein can be through natural means or synthetic. Screening 
of FtsZ inhibitors in extracts of microbial fermentation and plants found that viriditoxin 
selectively inhibited FtsZ polymerization and GTPase activity in vivo and in vitro without 
being toxic to eukaryotic cells (Wang et al. 2003). Other natural sources of FtsZ inhibition 
are polyphenols called zantrins which inhibit protein polymerisation by either 
destabilising FtsZ polymers or by stabilising FtsZ profilaments and altering Z ring 
assembly (Margalit et al. 2004; Buddelmeijer & Beckwith 2002). Another selective 
inhibitor which was developed by Läppchen et al. (2005) called 8-bromoguanosine 5’-
triphosphate was based on the structure of the natural substrate GTP. This compound 
had specific competitive inhibition of FtsZ polymerization and GTPase activity.  
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1.4.3 Mip inhibitors 
Juli et al. (2011) looked at various compounds to identify new small-molecule 
inhibitors of Mip by starting with known human T-cell FKBP (FKBP12) ligands (substance 
A and B) to test in L. pneumophila. These ligands bear a pipecoline moiety and so 
resemble the rapamycin anchoring group, but lack the macrocyclic portion thereby 
cancelling the immunosuppressive action. Out of the two substances, B, showed a good 
fit of the pipecoline-sulfonamide anchor group and was approached for synthesis into 
benzylsulfonamide. Experiments were conducted to test the interaction of the 
compound with Mip proteins and strong binding was observed (Juli et al. 2011). When 
the substance was tested on invasion and intracellular infection it was found that the 
substance did not influence replication of the wild-type in human macrophage-like U937 
cells. In contrast rapamycin treated wild-type L. pneumophila were not able to replicate 
in the cells or were degraded (Juli et al. 2011). These results suggest that Mip proteins 
are needed for virulence, however, PPIase activity may not be necessary for virulence. 
The target molecule for Mip mediated PPIase activity is still unknown and therefore, 
testing substance B once the target molecule has been identified will be more insightful 
(Juli et al. 2011).  
Similar to the L. pneumophila Mip inhibitor study, Begley et al. (2014) examined 
pipecolic acid derived compounds in B. pseudomallei. A wide selection of derivatives 
were tested which mimicked the pipecoline group of rapamycin and it was found that 
the racemic compounds 37 and 183 inhibited PPIase activity at low micromolar 
concentrations. The S enantiomer compound 168 and racemic compound 40 inhibited 
PPIase activity at high levels (Begley et al. 2014). When tested in a macrophage-based 
cytotoxicity assay, it was found that compounds 40, 160 and 183 significantly reduced 
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cytotoxicity by 30 – 40%. Compound 37 had decreased inhibitory activity however was 
higher than the control experiment (Begley et al. 2014). When tested in macrophage 
only controls, no cytotoxicity was observed for compounds 37 and 183, and less than 
10% cytotoxicity in compounds 40 and 160. Thus, the minimal cytotoxicity observed in 
non-infected macrophages provides evidence that this compound series has little 
adverse effect on the biological function of healthy mammalian macrophages in vitro 
and has great potential for drug development into novel inhibitors which target the Mip 
protein (Begley et al. 2014).   
1.5 In vitro models for novel inhibitor testing 
Before inhibitors can be tested in a clinical setting, extensive pre-clinical research 
must be conducted to assess the efficacy and safety of novel inhibitors. Many in vivo 
models exist to study host-microbe interactions and inhibitor testing. For example, 
insect models e.g. Galleria mellonella, zebrafish model and animal models such as mice. 
However, few in vitro models exist. In vitro models provide key aspects of infection and 
disease process in a physiologically relevant manner and simplify the process for 
analytical studies (MacGowan, Rogers & Bowker 2001; Crabbé, Ledesma & Nickerson 
2014). In vitro models are cost efficient and are less likely to raise ethical issues 
(Ramarao, Nielsen-Leroux & Lereclus 2012). As models need to be optimised for each 
individual bacterial species, model design is necessary to accurately test the efficacy of 
novel inhibitors. Some in vitro models that do exist include biofilm models, three-
dimensional (3D) tissue-engineered models and cell based models. These models 
provide a method by which to test the efficacy of novel inhibitors before using the more 
expensive in vivo infection models. 
31 
 
1.5.1 Biofilm models 
Biofilm growth models can be classified into two systems: open and closed. Closed 
models have the advantage of being simple and applicable in high-throughput analysis 
(Lourenço et al. 2014). An example of a closed system model is by using a micro titre 
plate such as a 96-well plate to inoculate bacterial culture and incubate at appropriate 
conditions for 24-48 hours. Biofilms form as a ring around the wells and washing the 
wells remove planktonic cells (Christensen et al. 1985). The remaining biofilm can be 
stained with crystal violet and dissolved in acetone to quantify biomass by measuring 
optical density (Christensen et al. 1985). This method is rapid and reproducible, 
however, the crystal violet stains both viable and dead cells and therefore the 
relationship between biomass and biofilm viability is unknown (Peeters, Nelis & Coenye 
2008).   
Open biofilm systems replicate in vivo conditions by controlling nutrient delivery, 
flow and temperature (Macià, Rojo-Molinero & Oliver 2014). The flow cell method 
utilises a vessel with sterile broth culture that provides medium through a peristaltic 
pump (Klausen et al. 2003; Nielsen et al. 2011). Bacteria are then directly inoculated into 
the flow cells by injection through silicone tubing. The cells are then attached to a 
surface such as a transparent, non-fluorescent microscope coverslip where biofilm 
formation can occur (Klausen et al. 2003; Nielsen et al. 2011). This process allows for a 
thicker biofilm however takes several days to prepare (Nielsen et al. 2011).  
1.5.2 3D tissue-engineering models 
3D tissue-engineered models consist of multiple cell types and a naturally formed 
extracellular matrix that mimic in vivo disease processes (Shepherd et al. 2009). 3D 
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tissue is engineered by seeding human skin (keratinocytes and fibroblasts) onto a 
decellularised dermis that is treated to retain its native basement membrane. After 10-
14 days of culture the reconstituted tissue resembles characteristics of normal human 
skin and can be infected with bacterial culture (Shepherd et al. 2009). Skin constructs 
can then be homogenised to determine viable bacterial counts or fixed in formalin for 
histological analysis (Shepherd et al. 2009). 3D tissue-engineered models provide a 
physiological similar structure to normal tissue and mimics the functions and responses 
of these tissues. However, a disadvantage of this model is the long culture time to form 
the tissue when comparing to two-dimensional cell monolayers (Mazzoleni, Di Lorenzo 
& Steimberg 2009). 
1.5.3 Cell based models 
Cell based models consist of a confluent monolayer of cells which are then infected 
with bacteria to determine virulence of the pathogen. Cell based models were used for 
testing the Mip inhibitors in L. pneumophila and B. pseudomallei (Juli et al. 2011; Begley 
et al. 2014). In the L. pneumophila Mip inhibitor study, macrophages were infected with 
bacteria in the presence of inhibitor and then extracellular bacteria were killed to 
enumerate intracellular bacteria only. Intracellular bacteria were then plated out on 
agar plates to determine colony-forming unit (CFU) counts, which is a measure of viable 
bacteria, to determine if the Mip inhibitors had an effect on internalisation and 
replication of the pathogen (Juli et al.2011).   
In the B. pseudomallei study, cytotoxicity assays were performed to assess the 
effects Mip inhibitors had on intracellular replication of the pathogen (Begley et al. 
2014). Confluent macrophage monolayers were infected with bacteria that had been 
pre-treated with Mip inhibitors. After infection, bacteria were removed and media was 
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added supplemented with antibiotic and inhibitor before incubation for 24 hours. After 
24 hours, cytotoxicity was measured by measuring lactate dehydrogenase release 
(Begley et al. 2014). Changes in lactate dehydrogenase release provided insight on the 
effects Mip inhibitors had on intracellular replication of B. pseudomallei. Cell based 
models are cost efficient and relatively easy to conduct making them attractive models 
for pre-clinical studies (Zang et al. 2012). 
1.6 Project aim 
This project aims to develop in vitro model methods, to test the potential broad-
spectrum activity of Mip inhibitors in K. pneumoniae and B. cenocepacia. To accomplish 
this aim, four objectives will be met.  
The first objective is to identify the homology between the K. pneumoniae Mip and 
the B. cenocepacia Mip against the L. pneumophila and B. pseudomallei Mip. To 
investigate this, online tools such as NCBI and ExPASy will be utilised. A multiple 
sequence alignment will then be created to compare the sequences of all four 
pathogens.  
The second and third objectives are to develop cell infection assay models to test 
the Mip inhibitors against adherence, and internalisation, survival and replication of the 
pathogens. Two methods will be developed. The first method will be to test the 
adherence capabilities of the bacterial species by challenging macrophages with K. 
pneumoniae and B. cenocepacia and counting the number of bacteria that were able to 
adhere to the macrophages via measurable plate counts. The second method will be to 
test the internalisation, survival and replication of K. pneumoniae and B. cenocepacia by 
challenging macrophages with K. pneumoniae and B. cenocepacia and counting the 
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number of bacteria that were able to internalise, survive and replicate in the 
macrophages via measurable plate counts at 0 hour and 24 hour post-infection. 
The final objective will be to use an optimised adherence assay and internalisation, 
survival and replication assay method to test the efficacy of the Mip inhibitors for K. 
pneumoniae and B. cenocepacia. By observing any changes in adherence and 
internalisation of bacteria in macrophages we can identify if inhibition of the Mip protein 
impacts virulence of the pathogens. 
1.7. Significance 
K. pneumoniae and B. cenocepacia are both MDR pathogens of public health 
interest that cause incredibly difficult to treat infections and increased morbidity and 
mortality rates. MDR strains of these bacteria are increasing in prevalence and some 
strains have become resistant to all current available first-line drug therapies. Research 
into common virulence targets of bacteria have become an attractive area of study as 
novel inhibitors is urgently needed. Mip proteins are part of the FKBP family and are 
encoded by pathogenic bacteria. They are involved in intracellular virulence of bacterial 
species and inhibition of the Mip protein via knock-out mutants or inhibitors have shown 
a decrease in virulence. This project will develop models to test the efficacy of Mip 
inhibitors and determine an optimised way of measuring the impact they have on 
interfering with virulence and replication. This project will also broaden the current 
knowledge available on Mip proteins and the effect Mip inhibitors have on virulence in 
K. pneumoniae and B. cenocepacia. By increasing our knowledge on Mip inhibition we 











2. Materials and methods 
2.1 Materials 
2.1.1 Bacterial strains and mammalian cell line 
K. pneumoniae strains used in this study are summarised in Table 2.1 and B. 
cenocepacia strains used in this study are summarised in Table 2.2 All strains were 
provided by Dr. T. J. J. Inglis, PathWest Laboratory Medicine WA, J block, QEII Medical 
Centre, Nedlands. The mammalian cell line used in this study was RAW264.7 mouse 
macrophage cells, provided by Professor Xu, School of Pathology and Laboratory 
Medicine, University of Western Australia. 
 
Table 2.1 K. pneumoniae strains used in this study 
 













MGH78578 K52 No No Yes 
ST23.1 K1 Yes Yes No 
ST23.2 K1 Yes Yes No 
ST86 K2 Yes Yes No 
ST628 Unknown No Yes No 
ST70 Unknown No Yes No 
ST14 K2 No Yes No 









164 III-B Yes No 
165 III-B Yes No 
167 III-C Yes No 
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2.1.2 Growth media and supplements 
Media used to grow the bacterial strains and RAW264.7 macrophage cells are 
summarised in Table 2.3. LB broth was stored at room temperature. LB agar plates, 
blood agar plates, Dulbecco’s Modified Eagle Medium (DMEM) and Leibovitz’s L-15 
Medium (L-15) were stored in the fridge at 4 °C. Supplements were added to media as 
required. GlutaMAXTM was stored in the fridge at 4°C. Foetal bovine serum (FBS) was 
aliquoted into 50 mL tubes and stored in the freezer at -20 °C. Supplements were added 
to DMEM by adding 10% FBS, 1% PenStrep and 1% GlutaMAXTM. Supplements were 
added to L-15 by adding 10% FBS.  
 
Table 2.3 Media and supplements used in this study 
 
2.1.3 Antibiotics and chemicals  
Antibiotics were added to media as required. Concentrations and preparation of 
antibiotics used for experiments are listed in Table 2.4. PenStrep was stored as 5 mL 
Media and supplements Supplier 
LB broth PathWest 
LB agar plates PathWest 
Blood agar plates PathWest 
DMEM 
Gibco by Life Technologies (USA) 
 L-15 
Gibco by Life Technologies (USA) 
GlutaMAXTM Gibco by Life Technologies 
FBS Gibco by Life Technologies 
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aliquots and kanamycin was filter sterilised using a 0.2 μm filter and stored as 1 mL 
aliquots. All antibiotics were stored in the -20 °C freezer.  
Chemicals used during the experiments are listed in Table 2.4. Prepared 1x 
phosphate-buffered saline (PBS) was autoclaved at 121 °C for 15 min, cooled and stored 
at room temperature. Triton-X was filter sterilised using a 0.2 μm filter and stored at 
room temperature. Dimethyl sulfoxide (DMSO) was stored at room temperature. Pre-
made PBS, GlutaMAXTM and TrypLETM were stored in the fridge at 4 °C and cytochalasin-
D was stored as 50 μL aliquots in the -20 °C freezer.  
 
Table 2.4 Antibiotics and chemicals used in this study 
 
 
Antibiotics and chemicals Composition Supplier 
PenStrep N/A Gibco by Life 
Technologies (USA) 
Kanamycin (50 mg/mL) 1g dissolved in 20mL dH2O 
Sigma-Aldrich chemical 
company (USA) 
Pre-made PBS N/A Gibco by Life 
Technologies (USA) 
PBS 
10mM disodium phosphate, 
156mM sodium chloride, 
2mM monopotassium 
phosphate 
Invitrogen by Life 
Technologies (USA) 
Cytochalasin-D (1 mg/mL) 1mg dissolved in 1mL DMSO Sigma-Aldrich chemical 
company (USA) 
Triton-X (1%) 500μL dissolved in 50mL PBS Sigma-Aldrich chemical 
company (USA) 
TrypLETM N/A Gibco by Life 
Technologies (USA) 
DMSO N/A Sigma-Aldrich chemical 
company (USA) 
Mip inhibitor 354 Dissolved in DMSO to a final 




Mip inhibitor 214 Dissolved in DMSO to a final 






2.1.4 Bioinformatic tools and software 
The Basic Local Alignment Search Tool (BLAST) from the National Centre for 
Biotechnology Information (NCBI) was utilised to identify Mip homologues in K. 
pneumoniae and B. cenocepacia. ClustalW-PBIL in ExPASy was used to create a multiple 
sequence alignment. GraphPad Prism 6 was used for statistical analysis and Excel 2013 
was used to create graphs and determine standard errors of the mean (SEM). 
2.2. Methods 
2.2.1 Bacterial recovery from glycerol stock and maintenance  
Bacterial strains were recovered by taking a loop full of glycerol bacterial stock 
stored in the -80 °C freezer and streaking onto blood agar plates. Plates were incubated 
under aerobic conditions at 37 °C overnight for K. pneumoniae and 48 hours for B. 
cenocepacia. After incubation, plates were stored in the fridge at 4 °C. Fresh blood agar 
plates were inoculated with glycerol bacterial stock every 2-3 weeks. 
2.2.2 Mammalian tissue culture 
2.2.2.1 Cell revival  
A vial containing RAW264.7 macrophage cells was rapidly thawed from storage in 
the -80 °C freezer and 1 mL of DMEM was added to the vial. The suspension was then 
transferred to a Sarstedt 15 mL tube and centrifuged at 423 x g for 5 min. The 
supernatant was discarded and 1 mL of DMEM was added to the cell pellet to resuspend. 
The 1 mL resuspension was then added to a culture flask containing 9 mL DMEM to make 




2.2.2.2 Cell passage and maintenance  
Confluent cell cultures were diluted into new culture flasks. The media was 
discarded and 5 mL of PBS was added to the flask to wash the cells. The PBS was then 
discarded and 5 mL TrypLETM was added to the flask and incubated at 37 °C for 15 min 
to allow dissociation of the cells. After incubation if the cells had not dissociated a 
scraper was used to remove all remaining adherent cells. The suspension was then 
transferred into a 15 mL tube and a 5 mL aliquot of DMEM was added to the cell 
suspension to deactivate the TrypLETM reaction. The cell suspension was then 
centrifuged at 423 x g for 5 min. The supernatant was discarded and 1 mL of DMEM was 
added to the 15 mL tube to resuspend the cell pellet. Required amount of resuspended 
cells was then added to a new flask with DMEM to make up a final volume of 10 mL. 
2.2.3 Cell infection assays 
2.2.3.1 Cell preparation for in vitro assays 
 RAW264.7 macrophage cells were prepared for infection assays by following the 
method outlined in section 2.2.2.2 until the centrifugation step. Cells were then diluted 
in DMEM and counted using a haemocytometer. Cells were made up to a concentration 
of 4 x 105 cells/mL and seeded onto Costar® 24-well plates by adding 1 mL of cell 
suspension to each well. The 24-well plates were then incubated overnight at 37 °C with 
5% CO2, achieving a confluent monolayer of 1 x 106 cells/mL the following day. 
2.2.3.2 Bacterial growth for in vitro assays  
Overnight cultures were prepared by inoculating 10 mL LB broth in a Sarstedt 30 
mL tube with a single bacterial colony from blood agar plates (section 2.2.1) and 
incubating overnight under aerobic conditions at 37 °C with agitation.  
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2.2.3.4 Dilution of overnight bacterial culture for enumeration and MOI calculations 
Overnight bacterial culture was prepared as outlined in section 2.2.3.2. The 
overnight culture was then diluted into LB broth to make up a final volume of 10 mL 
according to the following dilutions and vortexed in 30 mL tubes (Table 2.5). 
 
Table 2.5 Dilutions of overnight culture in media 
Neat tube Overnight culture Media Dilution 
1 500μL 9500μL 1 in 20 
2 1000μL 9000μL 1 in 10 
3 1500μL 8500μL 3 in 20 
 
 
Each 30 mL tube was labelled neat and was then serially diluted (1 in 10) from 10-1 
to 10-7 into LB broth in 24-well plates. Overnight culture, neat dilutions and subsequent 
dilutions were then measured using a spectrophotometer (Biochrom WPA CO7500 
Colorimeter) at an optical density of 600 nm. On LB agar plates, serial dilutions 10-6 and 
10-7 for each neat dilution were spread plate 3x with 100 μL aliquots of bacterial 
suspension and incubated overnight for K. pneumoniae and 48 hours for B. cenocepacia 
under aerobic conditions at 37 °C. Colonies were counted on each plate to determine 
CFU/mL (Appendix).  Each experiment was repeated three times. 
2.2.3.4.1 Overnight bacterial culture dilutions for in vitro assays 
Based on the results of the dilution experiments, overnight bacterial culture 
(section 2.2.3.2) was diluted in L-15 media until an absorbance reading of 0.25-0.35 was 
reached (depending on strain) for K. pneumoniae and 0.10-0.20 for B. cenocepacia for 
each in vitro assay conducted. This dilution was labelled as neat. The neat bacterial 
cultures were then serially diluted in L-15 (1 in 10) from 10-1 to 10-7. Serial dilutions 10-6 
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and 10-7 were spread plate 3x with 100 μL aliquots of bacterial suspension on LB agar 
plates and incubated overnight for K. pneumoniae and 48 hours for B. cenocepacia 
under aerobic conditions at 37 °C. The following day bacterial colonies were counted to 
determine CFU counts (Appendix).  
2.2.3.4 In vitro assays 
2.2.3.4.1 Adherence assays 
RAW264.7 macrophage cells were prepared the day before as outlined in section 
2.2.3.1. Overnight bacterial cultures were prepared as outlined in section 2.2.3.2. Dilute 
bacterial suspensions in L-15 media were prepared as outlined in section 2.2.3.3.1. The 
DMEM in the 24-well plates containing the RAW264.7 macrophage cells was discarded 
and 1 mL aliquots of L-15 media with 1 μg/mL cytochalasin-D was added to all wells and 
incubated at 37 °C under aerobic conditions for 30 min. Prior to infection, 1 μg/mL 
cytochalasin-D was added to dilute bacterial suspensions in L-15 media without 
incubation. After the 30 min incubation, the L-15 media with cytochalasin-D was 
discarded and 1 mL aliquots of dilute cytochalasin-D treated bacterial suspensions were 
added to wells containing pre-treated macrophages at an approximate multiplicity of 
infection (MOI) of 1:100 for K. pneumoniae and 1:200 for B. cenocepacia. For the 
controls, 1 mL aliquots of dilute cytochalasin-D treated bacterial suspensions were 
added to wells containing no macrophages. The 24-well plates were then incubated at 
37 °C under aerobic conditions for 1 hour. After incubation, bacterial suspensions were 
discarded from all wells, and the cells were subsequently washed 3x with 1 mL aliquots 
of PBS to remove non-adhered bacteria. Cells were subsequently lysed by adding 1 mL 
aliquots of 1% Triton X in PBS into all wells and incubated at 37 °C under aerobic 
conditions for 15 min. After incubation, wells were scraped and serially diluted (1 in 10) 
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in PBS. Each dilution was plated out on LB agar by dividing the agar plates into thirds and 
dropping three individual 100 μL aliquots of bacterial suspension onto each area (three 
drop method). Plates were then left to dry at room temperature and incubated 
overnight for K. pneumoniae and 48 hours for B. cenocepacia at 37 °C under aerobic 
conditions. The following day bacterial colonies were counted to calculate the 
concentration at which the bacteria adhered to the macrophages (Appendix). 
2.2.3.4.2 Internalisation, survival and replication assays 
RAW264.7 macrophage cells were prepared the day before as outlined in section 
2.2.3.1. Overnight bacterial cultures were prepared as outlined in section 2.2.3.2. Dilute 
bacterial suspensions in L-15 media were prepared as outlined in section 2.2.3.3.1. The 
DMEM in the 24-well plates containing the RAW264.7 macrophage cells was discarded 
and 1mL aliquots of dilute bacterial suspensions were added to the wells containing the 
macrophages at an MOI of 1:1000 for K. pneumoniae and 1:200 for B. cenocepacia. For 
the controls, 1 mL aliquots of dilute bacterial suspensions were added to wells 
containing no macrophages. The 24-well plates were then incubated at 37 °C under 
aerobic conditions for 1 hour. After incubation, bacterial suspensions were discarded 
from all wells and were subsequently washed 3x with 1 mL aliquots of PBS to remove 
extracellular bacteria. A 1 mL aliquot of 1 mg/mL kanamycin in L-15 media was then 
added to each well to kill any remaining extracellular bacteria and plates were incubated 
at 37 °C under aerobic conditions. After 1 hour incubation, 1 mL aliquots of 0.01% Triton 
X were added to all wells of the 0 hour time point and incubated at 37 °C under aerobic 
conditions for 15 min to lyse the macrophages. For the 24 hour time point, 1 mL aliquots 
of 250 μg/mL maintenance kanamycin in L-15 media was added to all wells and 
incubated at 37 °C under aerobic conditions until time point. After the 15 min 
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incubation, wells were scraped and serially diluted in PBS. Each dilution was plated out 
on LB agar using the three drop method (section 2.2.3.4.1). Plates were then left to dry 
at room temperature and incubated overnight for K. pneumoniae and 48 hours for B. 
cenocepacia at 37 °C under aerobic conditions. At the 24 hour time point, the L-15 media 
containing the maintenance kanamycin in each well was discarded. Triton X was then 
added to all wells to lyse the macrophage cells and wells were serially diluted and plated 
out on LB agar plates as mentioned above. Bacterial colonies were counted to calculate 
the concentration at which the bacteria internalised into the macrophages (Appendix). 
2.2.3.4.3 Mip inhibitor testing in adherence assays, and internalisation, survival and 
replication assays 
When testing the Mip inhibitors an extra step was added to incorporate the 
inhibitors into the assays. Before commencement of assays, dilute bacterial suspensions 
were dispensed in the required volume and incubated with each of the Mip inhibitors 
354 or 214 at a concentration of 5 mM at room temperature for 1 hour. For the DMSO 
controls, dilute bacterial suspensions in L-15 were incubated with DMSO at a 
concentration of 5 mM at room temperature for 1 hour. For the macrophage cell plus 
bacteria controls and the bacteria only controls, dilute bacterial suspensions were left 
at room temperature without any additives for 1 hour. The methods then followed as 
described in section 2.2.3.4.1 for the Mip inhibitor adherence assays and section 








Results of Objective 1 
Bioinformatic confirmation of putative Mip homologues in 
K. pneumoniae and B. cenocepacia, and quantitative 







3. Bioinformatic confirmation of putative Mip homologues in K. pneumoniae and B. 
cenocepacia, and quantitative determination of MOIs 
3.1 Strains 
The K. pneumoniae and B. cenocepacia strains used in this study are outlined in 
Table 2.1 and Table 2.2 respectively, of the materials section. K. pneumoniae strains 
were chosen because of their varying capsular types. B. cenocepacia strains were picked 
out of a variety of Bcc strains as it has been identified as the most prevalent pathogen 
of cystic fibrosis populations. 
3.2 Identification of Mip homologues in K. pneumoniae and B. cenocepacia through 
bioinformatic analysis 
The B. pseudomallei Mip sequence was used to search for homologues using the 
NCBI BLAST search tool. The homology was then compared between the putative K. 
pneumoniae Mip and B. cenocepacia Mip with the L. pneumophila and B. pseudomallei 
Mip. It was found that K. pneumoniae shared 41% and 52% with the L. pneumophila and 
B. pseudomallei Mip respectively and that B. cenocepacia shared 40% and 95% 
homology with the L. pneumophila and B. pseudomallei Mip respectively. Using the K. 
pneumoniae strain MGH78578 sequence (accession number ABR79951.1) and the B. 
cenocepacia sequence (accession number WP_009695294.1), a multiple sequence 
alignment was created with the online tool ClustalW-PBIL in ExPASy (Figure 3.1). Many 
regions of the sequence alignment were highly conserved between all four pathogens, 
especially the drug binding domains aspartic acid44 and tyrosine89 previously identified 
when the key active site of B. pseudomallei Mip was examined with nuclear magnetic 
resonance spectroscopy (NMR) and X-ray crystallography (Norville et al. 2011b). 




Figure 3.1 Alignment of the B. pseudomallei, B cenocepacia, K. pneumoniae and L. 
pneumophila Mip sequence  
K. pneumoniae shared 52% homology and 41% homology against the B. pseudomallei and 
L. pneumophila Mip sequence respectively. B. cenocepacia shared 95% homology and 
40% homology between the B. pseudomallei and L. pneumophila Mip sequence 
respectively. An asterisk (*) denotes a position with a single fully conserved residue, a 
colon (:) denotes conservation among groups of strongly similar properties and a full stop 
(.) denotes conservation among groups of weakly similar properties. Red highlighted 
residues indicate small + hydrophobic, blue highlighted indicates acidic, green highlighted 
indicate hydroxyl + sulfhydryl + amine + G. The boxed areas denote the key active site 








































3.3 Overnight dilution experiments 
The concentration of overnight bacterial culture was enumerated in order to 
calculate the MOI, which is the ratio in which the macrophages were infected with 
bacteria for each assay as a method of standardisation, as described in section 2.2.3.4. 
To determine the concentration of overnight bacterial cultures, cultures were diluted 
into three known dilutions of 1 in 20, 1 in 10 and 3 in 20. These dilutions were then 
serially diluted in LB broth and read by spectrophotometer at 600nm. Serial dilutions  
10-6 and 10-7 were spread plate onto agar plates for CFU counts. The CFU counts obtained 
the following day for K. pneumoniae and 48 hours for B. cenocepacia were then 
calculated to determine CFU/mL of overnight culture. 
3.3.1 K. pneumoniae dilution 
Strains MGH78578 and ST23.1 were used to determine the overnight concentration 
of K. pneumoniae cultures. Due to time constraints, all strains could not be tested, 
however, it was found that the K. pneumoniae strains had overnight concentrations 
ranging from approximately 1 x 1010 – 2.5 x 1010 and therefore, the same dilution was 
sufficient for each strain. It was found that the average overnight concentrations of 
MGH78578 and ST23.1 were 2.23 x 1010 CFU/mL and 1.19 x 1010 CFU/mL respectively. 
To calculate the MOI needed for each infection assay, the concentration of bacteria 
needed from overnight culture was 1 x 109 - 2 x 109 CFU/mL. It was found that a 1 in 10 
dilution gave the most accurate concentration range needed, when diluted to an OD600 





Figure 3.2 Dilution of K. pneumoniae strain MGH78578 overnight cultures 
Overnight concentration of strain MGH78578 cultures were an average of 2.23 x 




Figure 3.3 Dilution of K. pneumoniae strain ST23.1 overnight cultures 
Overnight concentration of strain ST23.1 cultures were an average of 1.19 x 1010 































1 in 20 1 in 10 3 in 20
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3.3.2 B. cenocepacia dilution 
Strains 164 and 165 were used to determine the overnight concentration of B. 
cenocepacia cultures. B. cenocepacia strains had overnight concentrations ranging from 
approximately 1.2 x 1010 – 3.0 x 1010 and therefore the same dilution was sufficient for 
each strain. It was found that the average overnight concentrations of strains 164 and 
165 were 1.21 x 1010 CFU/mL and 2.32 x 1010 CFU/mL respectively. To calculate the MOI 
needed for each infection assay, the concentration of bacteria needed from overnight 
culture was 1 x 109 – 2 x 109 CFU/mL. It was found that a 1 in 10 dilution gave the most 
accurate concentration range required when diluted to an OD600 of between 0.10 and 










Figure 3.4 Dilution of B. cenocepacia strain 164 overnight cultures 
Overnight concentration of strain 164 cultures were an average of 1.21 x 1010 




Figure 3.5 Dilution of B. cenocepacia strain 165 overnight cultures 
Overnight concentration of strain 165 cultures were an average of 2.32 x 1010 





































Results of Objective 2 
The assessment of K. pneumoniae and B. cenocepacia 
adherence to RAW264.7 macrophage cells as a model for 
inhibitor evaluation   
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4. The assessment of K. pneumoniae and B. cenocepacia adherence to RAW264.7 
macrophage cells as a model for inhibitor evaluation 
The developed assay method for testing the ability of K. pneumoniae and B. 
cenocepacia to adhere to the cell surface of RAW264.7 macrophage cells is described in 
section 2.2.3.4.1. Macrophages were pre-treated with cytochalasin-D for half an hour 
prior to infection with bacteria at an MOI of 1:100-200 (Figure 4.1). Cytochalasin-D was 
maintained at the same concentration throughout the experiment and a negative 
control of macrophages only was present to confirm no contamination had occurred 
throughout the experimental process. It was found that after washing to remove non-
adherent bacteria, K. pneumoniae and B. cenocepacia were adhering to the plastic of 
the 24-well plate and thus a positive control of bacteria only with no macrophages was 
implemented to compare the differences between the wells containing macrophages 
plus bacteria (experimental wells) and the wells containing bacteria only (control wells). 
 
 
Figure 4.1 Adherence assay model 
Confluent monolayers of macrophages were pre-treated with 1 μg/mL cytochalasin-D 
before infection with cytochalasin-D treated bacteria at an MOI of 1:100-200. Wells were 
incubated for 1 hour to allow bacteria to adhere to the macrophages. Cells were then 
washed, lysed and plated out on LB agar to determine viable bacterial counts. 
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4.1 K. pneumoniae adherence to RAW264.7 macrophage cells 
Eight K. pneumoniae strains were examined on their adherence capabilities: 
MGH78578, ST23.1, ST23.2, ST86, ST628, ST70, ST14 and ST770 (Figure 4.2). Strains 
MGH78578, ST628, ST70, ST14 and ST770 showed little difference in viable bacterial 
counts between the experimental wells and the control wells. This demonstrates that 
these strains were able to bind to the macrophages, however, there was also strong 
binding to the plastic of the 24-well plates. A difference between experimental wells and 
control wells was observed in strains ST23.1, ST23.2 and ST86. This indicates that these 
strains were also able to bind to the macrophages, but displayed binding to plastic at a 
lesser extent, in comparison to the other strains mentioned above. A notable 
observation was that strains ST23.1, ST23.2 and ST86 adhered to the macrophages at a 
lower concentration than the other strains (< 1.6 x 105 CFU/mL). When a paired t-test 
was conducted for statistical analysis between the experimental wells and the control 
wells of strains ST23.1 and ST86, a significant difference was seen (P > 0.009 and P > 







Figure 4.2 Concentration of K. pneumoniae that adhered to RAW264.7 
macrophage cells 
Macrophages were infected with K. pneumoniae for 1 hour at an MOI of 
1:100. An average of three individual assays for each strain is graphed. 
‘Bacteria + cells’ refers to the experimental wells and ‘bacteria only’ refers 
to the control wells. The asterisks shown for certain strains indicate 
significance.  One asterisk signifies P ≤ 0.05 whereas two asterisks signify P ≤ 








4.2 B. cenocepacia adherence to RAW264.7 macrophage cells 
Three strains of B. cenocepacia were tested for their adherence capabilities to 
RAW264.7 macrophage cells: 164, 165 and 167 (Figure 4.3). Experimentation for strains 
164 and 167 were repeated three times for statistical significance. However, due to time 
constraints, strain 165 was only experimentally repeated once and therefore no error 
bars and statistical analysis could be calculated. A difference was observed between the 
experimental wells and the control wells for all three strains. These results demonstrate 
that the B. cenocepacia strains were able to specifically bind to the macrophages and 
bind to the plastic of the 24-well plates, but to a lesser extent. The strains adhered to 
the macrophages between an average of 3.5 x 105 and 5 x 105 CFU/mL but only adhered 
to the plastic at an average of less than 2.5 x 105 CFU/mL.  A paired t-test was conducted 
for statistical analysis between the experimental wells and the control wells for strains 
164 and 167 and it was found that there was no significant difference. However, large 






Figure 4.3 Concentration of B. cenocepacia that adhered to RAW264.7 
macrophage cells 
Macrophages were infected with B. cenocepacia for 1 hour at an MOI of 
1:200. An average of three individual assays for each strain is graphed. 
‘Bacteria + cells’ refers to the experimental wells and ‘bacteria only’ refers 
to the control wells. The hashtag (#) indicates that strain 165 was only 
experimentally repeated once and therefore no statistical analysis or error 



























Results of Objective 3 
The assessment of K. pneumoniae and B. cenocepacia 
internalisation, survival and replication within RAW264.7 
macrophage cells as a model for inhibitor evaluation   
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5. The assessment of K. pneumoniae and B. cenocepacia internalisation, survival and 
replication within RAW264.7 macrophage cells as a model for inhibitor evaluation 
The developed method for testing internalisation, survival and replication of K. 
pneumoniae and B. cenocepacia is described in section 2.2.3.4. The macrophages were 
infected with an MOI of 1:1000 for K. pneumoniae and 1:200 for B. cenocepacia (Figure 
5.1). Two time points were examined, a 0 hour time point and a 24 hour time point post-
infection. A negative control of macrophages only was present to confirm that no 
contamination had occurred throughout the experimental process and a positive control 
of bacteria only was present to assure that all extracellular bacteria were killed during 
the 1 mg/mL kanamycin kill step.  
 
 
Figure 5.1 Internalisation, survival and replication assay model 
Confluent monolayers of macrophages were infected with bacteria at an MOI of 1:1000 for 
K. pneumoniae and 1:200 for B. cenocepacia. Wells were then incubated for 1 hour to allow 
bacteria to internalise into the macrophages. The wells were washed and 1 mg/mL 
kanamycin was added to kill all extracellular bacteria. Cells were then lysed and plated out 
on LB agar to determine viable bacterial counts. Two time points were observed; 0 hour 
and 24 hour post-infection. 
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5.1 K. pneumoniae internalisation, survival and replication within RAW264.7 
macrophage cells  
Seven strains of K. pneumoniae were tested for their ability to internalise, survive 
and replicate in the macrophages: ST23.1, ST23.2, ST86, ST628, ST70, ST14 and ST770 
(Figure 5.2). Two MOI ratios were tested, 1:100 and 1:1000. At the lower MOI no 
bacterial counts were obtained at the 0 hour time point and the 24 hour time point for 
all strains, suggesting that these strains either do not internalise into the macrophages 
or that the concentration of K. pneumoniae added to the macrophages is too low for 
successful internalisation. At the higher MOI of 1:1000, strains ST23.1, ST23.2, ST86, 
ST70 and ST770 demonstrated no internalisation into the macrophages at the 0 hour 
time point and the 24 hour time point (Figure 5.2). This demonstrates that these strains 
were not able to internalise into macrophages even when a higher concentration of 
bacteria was used.  
Strains ST628 and ST14 were the only two strains that were able to internalise into 
the macrophages at the 0 hour time point post-infection at an average of approximately 
27 CFU/mL and 5 CFU/mL respectively (Figure 5.2). Strain ST628 was able to internalise 
into the macrophages at the highest concentration in comparison to all other strains 
however, was not able to survive and replicate during 24 hours in the macrophages as 
no viable bacterial counts were obtained at this time point. Strain ST14 was the only 
strain that was able to survive and replicate during 24 hours in the macrophages with a 
5 fold increase in viable bacterial counts in comparison to the 0 hour time point. Even 
though certain strains demonstrated internalisation, survival and replication in 





Figure 5.2 Concentration of K. pneumoniae that internalised, survived and 
replicated within RAW264.7 macrophage cells 
Macrophages were infected with K. pneumoniae for 1 hour at an MOI of 
1:1000. An average of three individual assays for each strain is graphed. Two 
time points were observed, a 0 hour time point and a 24 hour time point post-
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5.2 B. cenocepacia internalisation, survival and replication within RAW264.7 
macrophage cells  
Three strains of B. cenocepacia were tested for their ability to internalise, survive 
and replicate in macrophages: 164, 165 and 167. At an MOI of 1:200 all B. cenocepacia 
strains were able to internalise into the macrophages at the 0 hour time point (Figure 
6.2A). When comparing the same graph on a logarithmic scale and linear scale it is seen 
that strain 165 was able to internalise at a much higher concentration (approximate 
average of 4 x 105 CFU/mL) than the other two strains tested (an average of less than 5 
x 104 CFU/mL in both strains 164 and 167) (Figure 6.2B). Furthermore, strain 165 was 
the only strain that suggests replication in the macrophages during a 24 hour period, 
with an approximate 1.25 fold increase in viable bacterial counts. In comparison, strains 
164 and 167 declined in the number of viable bacteria during 24 hours in the 










Figure 5.3 Concentration of B. cenocepacia that internalised, survived and 
replicated within RAW264.7 macrophage cells 
Macrophages were infected with B. cenocepacia for 1 hour at an MOI of 1:200. 
An average of three individual assays for each strain is graphed. Two time points 
were observed, a 0 hour time point and a 24 hour time point post-infection. ‘A’ 
is the results plotted on a logarithmic scale and ‘B’ is the results plotted on a 





































Results of Objective 4 
The effect of Mip inhibitors on adherence and, 
internalisation, survival and replication of K. pneumoniae 




6.  The effect of Mip inhibitors on adherence and internalisation, survival and 
replication of K. pneumoniae and B. cenocepacia in RAW264.7 macrophage cells 
The developed method for testing Mip inhibitors on adherence, internalisation, 
survival and replication of K. pneumoniae and B. cenocepacia is described in section 
2.2.3.5. Macrophages were infected with an MOI of 1:1000 for K. pneumoniae and 1:200 
for B. cenocepacia (Figure 6.1). The Mip inhibitors have been developed to bear a 
pipecoline moiety and resemble the rapamycin anchoring group but lack the macrocyclic 
portion, thereby cancelling the immunosuppressive action.  
The Mip inhibitors were dissolved in DMSO and thus a DMSO control was used to 
verify that no differences seen were due to the effects of the DMSO in the experiment 
rather than the Mip inhibitors. A negative control of macrophages only were present to 
make sure no contamination had occurred during the experimental process. A positive 
control of bacteria only was included for both adherence assays and internalisation, 
survival and replication assays. In regards to the adherence assays this was to compare 
the difference between bacteria only wells and the wells of the different variables (i.e. 
Mip inhibitors and DMSO (control)). In regards to the internalisation, survival and 
replication assays this was to assure that all extracellular were killed during the 1 mg/mL 
kanamycin killing step. Macrophages plus bacteria control wells were also added to 
make sure that bacterial counts that were being obtained were consistent with previous 







Figure 6.1 Mip inhibitor testing models 
Adherence assays (top pathway) and internalisation, survival and replication assays 
(bottom pathway) were conducted as previously outlined with the same MOIs 
however, to test the Mip inhibitors an added step was implemented as outlined in 










6.1. K. pneumoniae adherence to RAW264.7 macrophage cells with the Mip inhibitors 
The results outlined in section 4.1 for K. pneumoniae adherence to macrophages 
concluded that out of the eight strains tested, strains ST23.1 and ST86 showed a 
significant difference between the experimental wells and the control wells at an MOI 
of 1:100. Therefore, the Mip inhibitors were tested on these two strains to observe any 
effects of K. pneumoniae adherence to the macrophages in the presence of inhibitor as 
these strains were less able to bind to the plastic. Therefore, we can be confident that 
the bacteria recovered are bacteria that had adhered to the macrophages specifically. 
No difference in viable bacterial counts were observed between the DMSO control and 
the Mip inhibitors 354 and 214 for strain ST86, suggesting that the Mip inhibitors do not 
have an effect on adherence to RAW264.7 macrophage cells in this K. pneumoniae strain 
(Figure 6.2). A decrease was observed in strain ST23.1 adherence with Mip inhibitor 354 
by an approximate average of 1 x 105 CFU/mL in comparison to the DMSO control. 
Surprisingly an increase in adherence was observed in strain ST23.1 adherence with Mip 
inhibitor 214 in comparison to the DMSO control. Although there appeared to be a 
difference between the Mip inhibitors and the DMSO control in the number of viable 





Figure 6.2 Concentration of K. pneumoniae that adhered to RAW264.7 
macrophage cells with the Mip inhibitors 
Macrophages were infected with K. pneumoniae for 1 hour at an MOI of 
1:100 with Mip inhibitors 354 and 214 as well as DMSO (control). An average 

























6.2 B. cenocepacia adherence to RAW264.7 macrophage cells with the Mip inhibitors 
The results outlined in section 4.2 for B. cenocepacia adherence to RAW264.7 
macrophage cells found that no significant difference was observed between the 
experimental wells and the control wells for all three strains tested. Due to the lack of 
significance, limited time available and the limited Mip inhibitor available for testing, it 
was decided that testing the inhibitors on B. cenocepacia adherence to the macrophages 
will not go ahead. 
6.3 K. pneumoniae internalisation, survival and replication within RAW264.7 
macrophage cells with the Mip inhibitors 
The results outlined in section 5.1 concluded that K. pneumoniae strains ST628 and 
ST14 were the only two strains out of the seven strains tested that internalised, survived 
and replicated within the RAW264.7 macrophage cells at an MOI of 1:1000. Strain ST628 
was internalised into the macrophages however was not able to survive and replicate 
during 24 hours post-infection. Strain ST14 was the only strain to show internalisation, 
survival and replication during 24 hours. Based on these results, strains ST628 and ST14 
were chosen for Mip inhibitor testing. For strain ST628 only the 0 hour time point was 
examined post-infection as no bacterial counts were observed at the 24 hour time point. 
For strain ST14 however, inhibitors were tested at both the 0 hour time point and at the 
24 hour time point.  
When the Mip inhibitors 354 and 214 were tested in strain ST628 at the 0 hour time 
point post-infection, statistical analysis found no significant difference (Figure 6.3). This 
was perhaps due to the high variability of individual assays and thus, further repetition 
of the experiments is required to increase statistical power. Therefore, to examine the 
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effects of the Mip inhibitors in the internalisation of this strain, trends were examined 
across three individual replicates. Two of three assays conducted showed a decrease in 
the number of viable bacteria obtained with the Mip inhibitors, in comparison to the 
DMSO control. An approximate 40% decrease in viable bacterial counts was observed 
with both inhibitors in experiment 1, and an 80% and 60% decrease in viable bacterial 
counts was observed with inhibitor 354 and 214 respectively, in experiment 2. An 
increase in the number of viable bacteria was observed with both inhibitors in 
experiment 3 (Figure 6.3).  
 When testing the effect of the Mip inhibitors on strain ST14 it was found that the 
inhibitors did not have a demonstrable effect on the internalisation, survival and 
replication of this strain (Figure 6.4). Surprisingly, at the 0 hour time point an increase in 
viable bacterial counts was observed for both inhibitors, particularly inhibitor 214, in 
comparison to the DMSO control. Again at the 24 hour time point, an increase in the 
number of viable bacteria that had survived and replicated in the macrophages was 
observed with inhibitor 214. A slight decrease in the number of viable bacteria 
(approximate average of > 2 CFU/mL) was suggested with the presence of inhibitor 354 
at the 24 hour time point. However, statistical analysis of the data found no significance. 





Figure 6.3 Concentration of K. pneumoniae strain ST628 that was 
internalised into the RAW264.7 macrophage cells with the Mip inhibitors 
Macrophages were infected with K. pneumoniae strain ST628 for 1 hour at 
an MOI of 1:1000 with Mip inhibitors 354 and 214, as well as DMSO (control). 
Results of three individual assays (experiments) are graphed to examine 


















Figure 6.4 Concentration of K. pneumoniae strain ST14 that internalised, 
survived and replicated within RAW264.7 macrophage cells with the Mip 
inhibitors 
Macrophages were infected with K. pneumoniae strain ST14 for 1 hour at an 
MOI of 1:1000 with Mip inhibitors 354 and 214, as well as DMSO (control). An 

























6.4 B. cenocepacia internalisation, survival and replication in RAW264.7 macrophage 
cells with the Mip inhibitors 
The results in section 6.2 concluded that the only B. cenocepacia strain which was 
able to replicate in the RAW264.7 macrophage cells at an MOI of 1:200 during a 24 hour 
period was strain 165. Strains 164 and 167 declined in viable bacterial counts during 24 
hours in the macrophages. Therefore strain 165 was chosen for Mip inhibitor testing. 
Mip inhibitors 354 and 214 were tested at both the 0 hour time point and at the 24 hour 
time point post-infection to determine if there was a decrease in the number of viable 
bacterial with inhibitor.  
Statistical analysis of the data found that no significant difference was observed 
when a paired t-test was conducted. This was due to the high variability of individual 
assays and thus, further repetition of the experiments are required to increase statistical 
power. Therefore, to examine the effects of the Mip inhibitors in the internalisation, 
survival and replication of this strain, trends were examined across the three individual 
experimental replicates (Figure 6.5). At the 0 hour time point, a decrease in viable 
bacterial counts was observed with inhibitor 354 in comparison to the DMSO control in 
two out of the three assays conducted. Experiment 3 in particular showed a 30% 
decrease with inhibitor 354. Minor differences were observed with inhibitor 214 in 
viable bacterial counts between individual assays at the 0 hour time point. 
At the 24 hour time point, a decrease in viable bacterial counts were observed with 
Mip inhibitor in two out of the three assays conducted. In experiment 1, there was an 
approximate 30% decrease in viable bacterial counts with both inhibitors, and in 
experiment 2 there was an approximate 20% and 30% decrease in viable bacterial 
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counts with inhibitor 354 and 214 respectively. Little change was observed in 
experiment 3 with the inhibitors (Figure 6.5). 
 
 
Figure 6.5 Concentration of B. cenocepacia strain 165 that internalised, 
survived and replicated within RAW264.7 macrophage cells with the Mip 
inhibitors 
Macrophages were infected with B. cenocepacia strain 165 for 1 hour at an 
MOI of 1:200 with Mip inhibitors 354 and 214, as well as DMSO (control). 
Results of three individual assays (experiments) are graphed to examine 




















K. pneumoniae and B. cenocepacia are important emerging pathogens and 
contribute to the rise of MDR infections (Arnold et al. 2011; Zhou et al. 2007). K. 
pneumoniae is capable of severe and possibly fatal infections, which include pneumonia, 
urinary tract infections, liver abscesses and septicaemia (Prince et al. 1997; Lin et al. 
2014; Pope et al. 2011). Secondary complications such as vision loss, necrotising fasciitis 
and meningitis from metastatic spread occur (Siu et al. 2012). B. cenocepacia is most 
common in individuals who have cystic fibrosis and chronic granulomatous disease due 
to the immunodeficiency observed in these disease states, resulting in persistence of 
infection (Speert 2002; Govan, Hughes & Vandamme 1996). Infections cause severe 
pulmonary inflammation, pneumonia and septicaemia (Sajjan et al. 2008). ‘Cepacia 
syndrome’ is a devastating characteristic of this pathogen causing rapid deterioration in 
lung function and subsequent multi-organ failure (Blackburn et al. 2004).  
Very few antibiotics remain universally effective for these pathogens. For example, 
KPC strains are able to hydrolyse penicillins, all cephalosporins, monobactams, 
carbapenems, and β-lactamase inhibitors (Papp-Wallace et al. 2010). B. cenocepacia is 
naturally resistant to a wide range of antibiotics due to the many mechanisms of 
antibiotic inhibition (Drevinek & Mahenthiralingam 2010). An increase in nosocomial 
infections due to these pathogens, have resulted in prolonged morbidity and increased 
mortality rates (Ramsay et al. 2013; Arnold et al. 2011). Therefore, the need for novel 
inhibitors is evident. Bacteria exhibit many common virulence targets which can be 
inhibited for potential broad-spectrum activity. For example, inhibiting quorum sensing 
and cell division amongst others (O’Loughlin et al. 2013; Läppchen et al. 2005). A 
virulence target which was first identified in L. pneumophila is the Mip protein 
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(Cianciotto et al. 1989). Other Mip-like proteins have been identified in B. pseudomallei, 
C. trachomatis, N. gonorrhoeae and T. cruzi (Norville et al. 2011a; Lundemose, Kay & 
Pearce 1993; Leuzzi et al. 2005; Moro et al. 1995). 
Mip proteins have been identified as bacterial FKBPs which are involved in 
intracellular virulence in a number of pathogens. FKBPs are highly conserved proteins 
that bind to the immunosuppressive compounds FK506 and rapamycin, and display 
peptidylprolyl cis/trans isomerase (PPIase) activity (Göthel & Marahiel 1999; Barik 
2006). Due to their highly conserved nature, it is believed that putative Mip proteins are 
present in K. pneumoniae and B. cenocepacia. Mip inhibitors have been developed to 
mimic the rapamycin anchoring group but lack the immunosuppressive actions of the 
compound. Therefore, they do not affect human FKBPs (Juli et al. 2011). When tested in 
L. pneumophila and B. pseudomallei, a decrease in virulence was observed (Juli et al. 
2011; Begley et al. 2014).  
As Mip proteins have been identified in a range of bacteria, the inhibitors have been 
proposed to have potential broad-spectrum activity. In order to assess this potential 
broad-spectrum activity in vitro, a model must be developed. A few models are available 
for in vitro testing which include biofilm models, 3D tissue-engineering models and cell 
based models (Lourenço et al. 2014; Shepherd et al. 2009; Begley et al. 2014). These 
models provide key aspects of infection and disease in a simplified manner for analytical 
studies. Therefore, the aim of this study was to develop in vitro infection model methods 




7.1 Bioinformatic confirmation of putative Mip homologues in K. pneumonia and B. 
cenocepacia 
The first objective was to use bioinformatic tools to confirm the presence of 
putative Mip homologues in K. pneumoniae and B. cenocepacia. This was done by 
performing a BLAST search against the B. pseudomallei and L. pneumophila Mip 
sequence. The putative K. pneumoniae Mip was identified to be 52% and 41% 
homologous to the B. pseudomallei and L. pneumophila Mip respectively and the 
putative B. cenocepacia Mip was identified to be 95% and 40% homologous to the B. 
pseudomallei and L. pneumophila Mip respectively. These values are notable sequence 
identities due to the many regions which were highly conserved between all four 
pathogens (Figure 3.1). 
Analysis of the L. pneumophila Mip identified that the protein is a surface expressed 
lipoprotein that contains an N-terminal dimerisation and chaperone domain and a C-
terminal PPIase domain (Riboldi-Tunnicliffe et al. 2001). The active site of FK506, is a 
cavity containing a number of hydrophobic residues that are highly conserved between 
members of the FKBP family (Riboldi-Tunnicliffe et al. 2001). X-ray and NMR structural 
investigation of the B. pseudomallei Mip observed that a number of amino acid side 
chains displayed multiple conformations (Norville et al. 2011b). Most were distant from 
the active site, however in the active site two amino acids in particular showed 
significant flexibility; Aspartic acid44 and tyrosine89, outlined in the black boxes (Figure 
3.1). It was found that the same flexibility was not observed in human FKBP12 (Szep et 
al. 2009). These amino acids provide the only source of hydrogen-bond donors and 
acceptors in the B. pseudomallei Mip active site and when these residues were mutated 
in the L. pneumophila Mip, a significant reduction in enzyme activity was observed 
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(Wintermeyer et al. 1995). The unusual flexibility of these highly conserved side chains 
suggest that they play a role in catalysis (Norville et al. 2011b).  
As aspartic acid44 and tyrosine89 are highly conserved between all four pathogens, 
and these amino acids have been identified as key residues in the active site of the B. 
pseudomallei and L. pneumophila Mip, it is likely that the putative Mip proteins 
identified in K. pneumoniae and B. cenocepacia are involved in virulence as well. 
However, the proteins have not yet been studied in these pathogens. As the mutation 
of these amino acids results in a significant reduction in enzyme function, the residues 
are important drug binding domains. Therefore, based on the results of the sequence 
alignment there is sufficient evidence that both K. pneumoniae and B. cenocepacia 
contain Mip-like proteins. However, their function in these pathogens and whether they 
are involved with virulence is still unknown.  
7.2 The assessment of K. pneumoniae and B. cenocepacia adherence to RAW264.7 
macrophage cells as a model for inhibitor evaluation 
The second objective was to identify the magnitude at which K. pneumoniae and B. 
cenocepacia adhere to RAW264.7 macrophage cells. This was achieved by developing 
an adherence assay method which would be suitable for inhibitor evaluation of bacterial 
adhesion to the macrophages, as described in section 2.2.3.4.1. The method developed 
was simple, quantitative and required little equipment. The only technical challenge that 
arose when conducting the adherence assays was that non-specific abiotic binding was 
observed in the control wells for K. pneumoniae and B. cenocepacia. Therefore, even 
though a confluent monolayer of macrophage cells was present at the bottom of each 
experimental well, there was potential for non-specific abiotic binding to the sides of 
the wells. An improvement would be to determine a way to measure specific binding. 
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For example, using microscopic enumeration of macrophage bound bacteria as a direct 
measure rather than enumeration via plate counts. Despite this, the method described 
in this study worked well with both K. pneumoniae and B. cenocepacia and 
demonstrated that these pathogens were able to adhere specifically and non-
specifically. 
7.2.1 K. pneumoniae adherence to RAW264.7 macrophage cells 
K. pneumoniae strains MGH78578, ST628, ST70, ST14 and ST770 displayed specific 
binding to macrophages but had strong non-specific binding to the plastic of the 24-well 
plates (Figure 4.2). A difference was observed between the experimental wells and the 
control wells of strains ST23.1, ST23.2 and ST86, suggesting that these strains were able 
to adhere to the macrophages but were less able to adhere to the plastic. An interesting 
observation of ST23.1, ST23.2 and ST86 was that they adhered to the macrophages at a 
lower concentration than the other strains mentioned above.  
Two major virulence factors which are linked to pathogenicity of K. pneumoniae are 
the pili and capsular polysaccharides. Pili are found on the surface of the bacterium and 
bind to host cells (Ofek & Beachey 1978; Venegas et al. 1995; Hornick et al. 1992; 
Tarkkanen et al. 1997). They are also associated with biofilm formation on biotic and 
abiotic surfaces (Schroll et al. 2010; Boddicker et al. 2006). Capsular polysaccharides 
protect the bacterium from phagocytosis and serum killing (Podschun, Penner & Ullman 
1992; Williams et al. 1983). Studies conducted on the relationship of capsule and 
adherence have found that encapsulated K. pneumoniae strains impede the function of 
type 1 pili and therefore decrease their ability to adhere to cells and agglutinate yeast 
cells, which tests the mannose-binding phenotype of type 1 pili, because of the physical 
interference of the capsule (Sahly et al. 2000; Schembri et al. 2005). 
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A unique feature of strains ST23.1, ST23.2 and ST86 that was not seen in the other 
strains of this study was the mucoviscosity identified by the stretchability of the colonies 
on agar plates when a bacterial loop was passed through. Even though the presence of 
pili was not tested in this study, this occurrence could explain why a lower concentration 
of bacteria was observed in strains ST23.1, ST23.2 and ST86. The over-expression of 
capsule may physically hide the pili, lowering their ability to bind to the macrophages.  
Pili are also partly responsible for non-specific binding to abiotic surfaces as well as 
biofilm formation (Schroll et al. 2010; Di Martino et al. 2003). As the pili were most likely 
hidden in these strains due to the thick capsule, this may also explain why a lower 
concentration of viable bacteria were obtained in the control wells, in comparison to 
the other strains tested (Figure 4.2).  
The capsular type for strains ST23.1, ST23.2 and ST86 are K1, K1 and K2 respectively. 
Epidemiological studies on the prevalence of various capsular types have found that K1 
and K2 isolates are predominantly isolated from individuals in South East Asia, and cause 
metastatic liver abscesses, pneumonia, urinary tract infections and bacteraemia (Liu, 
Wang & Jiang 2013; Feizabadi, Raji & Delfani 2013; Ko et al. 2002). These capsular types 
are also strongly associated with hypervirulent K. pneumoniae due to the mucoid 
appearance and stretchability on agar plates, which is attributed to an increase in 
capsule production by the acquisition of the rmpA gene located on a large virulence 
plasmid (Cheng et al. 2010). As it has been demonstrated that capsule impedes the 
function of pili due to a physical hindrance, and the literature suggests that strains of 
thick mucoid capsules particularly of K1 and K2 capsular types are most associated with 
MDR invasive infections, it is likely that other mechanisms that extend out of the thick 
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capsule may be involved in adherence to host cells as well as biofilm formation in these 
strains.  
In strains MGH78578, ST628, ST70, ST14 and ST770, little difference was observed 
between the experimental wells and the control wells in the number of viable bacteria 
obtained (Figure 4.2). In regards to these strains that were able to bind to the 
macrophages but also strongly bind to the plastic, the capsule was not as mucoviscous 
as they did not stretch from the agar plates when bacterial loops were passed through. 
Based on this observation, it can be concluded that these strains are not mucoid 
producing K. pneumoniae and therefore the capsule does not impede the function of pili 
to the same extent as mucoid producing strains, allowing specific-binding to the 
macrophages. The pili may also be exposed to allow abiotic adherence as well as biofilm 
formation which may explain why a high number of viable bacteria were obtained in the 
control wells. The formation of biofilms in the plastic may also contribute to the high 
bacterial counts as they were still attached to the plastic even after washing. 
7.2.2 B. cenocepacia adherence to RAW264.7 macrophage cells 
B. cenocepacia strains 164, 165 and 167 were able to adhere to the macrophages 
at an approximate average of 3.5 x 105 CFU/mL to 5.0 x 105 CFU/mL (Figure 4.3). Early 
studies have identified that the adhesins of B. cenocepacia are important in adherence 
and colonisation of the respiratory tract. In particular, the cable pili has been identified 
as one of the main virulence factors of B. cenocepacia (Urban et al. 2005). Previous 
analysis of these strains conducted by Adam Merritt from PathWest Laboratory 
Medicine WA found that they do not contain the cblA gene needed for cable pili 
formation. The absence of this gene did not affect these B. cenocepacia strains’ ability 
to adhere to the macrophages and therefore other mechanisms are involved with 
83 
 
adherence of B. cenocepacia to host cell. These results are consistent with a study that 
created a cblA null mutant. No significant difference in adherence was observed in 
mucin and epithelial cell attachment between the mutant strain and the wild-type 
strain, suggesting that other mechanisms of adherence besides the cable pili are 
involved (Tomich & Mohr 2003).  
A study conducted by Mil-Homens and Fialho (2011) found that the highest number 
and density of putative TAAs observed in the Bcc was in the B. cenocepacia genomovar. 
It is unknown if all TAAs have unique functions or are redundant but this may explain 
why B. cenocepacia has elevated pathogenicity in comparison to other Bcc species, 
identified in the literature. The presence of TAAs along with other mechanisms have 
been associated with biofilm formation, which may explain why bacterial counts were 
observed in the control wells of the B. cenocepacia strains even after washing. It is 
evident that B. cenocepacia has an array of mechanisms for adherence causing the 
bacterium to be more pathogenic however, these mechanisms have not been fully 
explored. 
7.3 The assessment of K. pneumoniae and B. cenocepacia internalisation, survival and 
replication within RAW264.7 macrophage cells as a model for inhibitor evaluation 
The third objective was to identify the magnitude at which K. pneumoniae and B. 
cenocepacia are internalised, survive and replicate in RAW264.7 macrophage cells after 
24 hours post-infection. This was achieved by developing an internalisation, survival and 
replication assay method which would be suitable for inhibitor evaluation in both 
pathogens as described in section 2.2.3.4.2. For these assays two time points were 
examined post-infection; a 0 hour time point and a 24 hour time point. Again, the assay 
method was simple and quantitative and little equipment was required. No real 
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improvements were needed for the developed method as sufficient results were 
obtained for both pathogens, however, an alternative way of enumerating bacteria 
would be to use fluorescent microscopy to count viable internalised bacteria. This would 
be particularly useful for strains which are MDR, as was observed in the K. pneumoniae 
strain MGH78578 of this study. This strain could not be killed with 1 mg/mL kanamycin 
and therefore internalised bacteria could not be distinguished from external bacteria 
based on plate counts. 
7.3.1 K. pneumoniae internalisation, survival and replication within RAW264.7 
macrophage cells 
Results of the internalisation, survival and replication assays demonstrated that 
two K. pneumoniae strains, ST628 and ST14, were internalised into the macrophages at 
an MOI of 1:1000 after 1 hour of infection (Figure 5.2). Strain ST628 was internalised at 
the 0 hour time point post-infection but was not able to survive and replicate during 24 
hours in the macrophages. ST14 was the only strain that was internalised at the 0 hour 
time point and replicated during 24 hours in the macrophages, with a 5 fold increase in 
viable bacterial counts. All other strains were not internalised into the macrophages at 
a high MOI after 1 hour of infection and thus seem to be extracellular pathogens, based 
on the results of this study. 
K. pneumoniae is known as an extracellular pathogen. However, it has been 
demonstrated that these pathogens have the ability to internalise into epithelial cells 
(Oelschlaeger & Tall 1997; Fumagalli et al. 1997; Hsu et al. 2015). Oelschlaeger and Tall 
(1997) demonstrated that once attachment had occurred to the epithelial cell surface, 
trigger mechanism(s) for invasion depended on microfilaments, microtubules and a 
receptor which reflects receptor-mediated endocytosis. Local actin cytoskeleton 
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rearrangement within the host leads to the formation of protrusions that engulf and 
enclose the bacteria (Kochut & Dersch 2013). In addition to these mechanisms, Hsu et 
al. (2015) found that hijacking host machinery Rho family GTPases and the 
phosphatidylinositol 3-kinase/Akt signalling pathway is important in internalisation into 
intestinal epithelium. Rho family GTPases control many processes including cell 
proliferation and regulation of the actin cytoskeleton. Regulatory proteins of 
phosphatidylinositol 3-kinase and Akt are also involved in many cell processes such as 
the regulation of actin polymerisation and the promotion of microtubule stabilisation. 
In order for K. pneumoniae to be internalised into host cells, it has been proposed that 
the pathogen is capable of modulating phosphatidylinositol 3-kinase and Akt to control 
both actin and microtubule dynamics during internalisation (Hsu et al. 2015).  
When comparing the K2 capsular strains ST86 and ST14 it was observed that strain 
ST86 produced mucoid colonies on agar plates however, strain ST14 did not appear to 
have mucoid colonies on agar plates. Even though both strains are classified into the 
same capsular type it seems that the overexpression of capsule is physically hiding the 
adherence and possible internalisation mechanisms required for invasion in strain ST86 
(Figure 5.2). As the capsule is not as prominent in strain ST14 the mechanisms required 
for internalisation may be exposed resulting in internalisation of this K2 variant. Very 
little is known about strain ST628 including the capsular type which limits the 
conclusions that can be made however, it is evident that both ST628 and ST14 contain 
mechanisms to promote internalisation into the macrophages which are not present in 
the other strains of this study. Based on the results of these internalisation, survival and 
replication assays in K. pneumoniae it is observed that internalisation is strain 
86 
 
dependent irrespective of capsular type and that many strains most likely exist as 
extracellular pathogens.  
7.3.2 B. cenocepacia internalisation, survival and replication within RAW264.7 
macrophage cells 
Martin and Mohr (2000) demonstrated that both a clinical isolate from the 
epidemic ET12 lineage and an environmental isolate of B. cenocepacia are able to be 
internalised into human macrophage and epithelial cells. When comparing the 
intracellular growth of both these isolates over a 24 hour period, the environmental 
isolate was not able to replicate over the 24 hour period however the epidemic clinical 
strain increased by a log10 unit and then maintained this concentration between the 18 
and 24 hour time points. The mechanisms associated with B. cenocepacia 
internalisation, survival and replication have previously been investigated. It was found 
that the bacterium’s flagella is important in initiation and contact of bacteria to host cell 
and that a flagella formation gene knockout mutant had an impaired ability to invade 
A549 epithelial cells (Tomich et al. 2002). Like L. pneumophila, B. cenocepacia is capable 
of modulating phagosomal development as well as inhibiting the fusion of phagosome 
to lysosomes, thereby allowing the bacteria to survive within the phagosome causing 
persistent infections (Lamothe et al. 2007).  
Two of the three clinical B. cenocepacia strains of this study were unable to 
replicate during 24 hours in the macrophages. However, strain 165 was able to replicate 
during a 24 hour period (Figure 5.3). This strain did not replicate a substantial amount 
in comparison to the clinical isolate studied by Martin and Mohr (2000) however an 
approximate average increase of 1 x 105 CFU/mL was observed. It is unknown at what 
time point the strain replicated as only two time points were used in this study and 
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therefore it would be interesting to see if replication occurred early after post-infection 
before becoming stagnant at the 24 hour time point, or if there was rapid replication 
and then a slow decline near the 24 hour time point.  
The results obtained from this study are consistent with past literature. Based on 
the literature it seems strain 165 is able to evade phagosomal degradation by 
modulating the maturation of phagosomes, survive within the phagosome, replicate and 
promote dissemination. Strains 164 and 167 may not contain the required machinery to 
evade phagosomal degradation and fusion to lysosomes however, as viable bacteria 
were obtained after the 24 hour time point it seems that these strains are able to 
prolong the process of phagosomal degradation. Thus, it was found that B. cenocepacia 
can be internalised by macrophage cells, however the fate of these bacteria in their 
ability to survive and replicate over a period of time is strain dependent. 
7.4 The assessment of the effects of Mip inhibitors on adherence, and internalisation, 
survival and replication of K. pneumoniae and B. cenocepacia within RAW264.7 
macrophage cells 
After identifying the presence of putative Mip proteins in K. pneumoniae and B. 
cenocepacia as well as the magnitude at which these pathogens adhered, internalised, 
survived and replicated in RAW264.7 macrophage cells, the final objective was to assess 
the effects of Mip inhibitors 354 and 214 on infectivity of K. pneumoniae and B. 
cenocepacia. This was achieved by adding an additional step to the adherence assay, 
and internalisation, survival and replication assay methods as described in section 
2.2.3.4.3. The extra incubation time with Mip inhibitor was not accounted for in the 
assays without inhibitor and due to the high MOI that was used for K. pneumoniae 
internalisation, survival and replication assays, this affected the experiments. The high 
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concentration of bacteria resulted in the media to change yellow prior to infection of 
the macrophage cells; an indicator of low pH. The low pH could not sustain macrophage 
cell survival and resulted in cell death. To overcome this, bacteria were centrifuged at 
600 x g for 10 min after incubation with Mip inhibitors and then fresh media was added 
to the same volume for subsequent macrophage cell infection. This slight change in the 
method was only required for the assays with an MOI of 1:1000. No Mip studies in K. 
pneumoniae and B. cenocepacia could be found when searching the literature and thus, 
this is the first Mip study in these pathogens.  
7.4.1 K. pneumoniae and B. cenocepacia adherence to RAW264.7 macrophage cells 
with the Mip inhibitors 
It is known that Mip proteins are involved with intracellular infection of a number 
of pathogenic bacteria however, very little is known on whether these proteins are 
involved with extracellular early stage infection prior to internalisation. In L. 
pneumophila it was found that the first known extracellular function of Mip proteins 
was its ability to bind to the extracellular matrix of lung epithelial cells and to collagen I-
VI via its C-terminal PPIase domain (Wagner et al. 2007). However, when looking at the 
possibility of Mip proteins being involved with adherence, it was found that these 
proteins were not involved with adherence of N. gonorrhoeae to macrophage cells and 
B. pseudomallei to epithelial cells when compared to a knockout mutant (Leuzzi et al. 
2005; Norville et al. 2011a).  
Strains ST23.1 and ST86 were specifically chosen because not only were they K1 
and K2 capsular type, which are most prevalent in K. pneumoniae infections, but a 
significant difference was observed between the experimental wells and the control 
wells. The significant difference implied that these strains were able to bind to the 
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macrophages but were less able to non-specifically bind to the plastic in comparison to 
the other strains which displayed strong non-specific binding (Figure 4.2). Using strains 
ST23.1 and ST86 assures that the bacteria obtained from inhibitor testing are most likely 
bacteria that had adhered to the macrophages.  
When testing the Mip inhibitors 354 and 214 in K. pneumoniae strains ST23.1 and 
ST86 no significant difference was observed between the DMSO control and the 
inhibitors for both strains, particularly in strain ST86 where very little difference was 
observed (Figure 6.2). It seems that either Mip proteins are not present in this strain, 
the Mip inhibitors are not binding efficiently to the putative protein’s active site or the 
function of Mip is not involved in the adherence of bacteria to macrophages. In strain 
ST23.1 a slight decrease in viable bacterial counts was observed with Mip inhibitor 354, 
however, an increase in viable bacteria counts was observed with Mip inhibitor 214, in 
comparison to the DMSO control. Despite this, these results were not significant and 
large error bars were observed. Therefore, it is hard to draw conclusions on whether the 
Mip inhibitors (particularly inhibitor 354) had an effect on adherence in this K. 
pneumoniae strain and whether Mip proteins are involved with adherence to 
macrophage cells. 
As discussed previously, on further insight into the literature it was found that the 
capsule of K. pneumoniae strains impede the function of pili due to the capsule 
physically hiding the pili (Sahly et al. 2000; Schembri et al. 2005). As ST23.1 and ST86 
were mucoid colony producing strains it is likely that the pili were hidden, decreasing 
their ability to bind to the macrophages as was observed in the results (Figure 4.2). 
Therefore it seems that the other non-mucoid producing strains would have been better 
suited to test Mip inhibitors as the capsule would not impede function of pili to the same 
90 
 
extent as mucoid strains. Even though these strains show strong non-specific binding to 
the plastic it would be interesting to see if Mip proteins have an effect on these strains, 
as their ability to adhere to the macrophage cells is also higher (Figure 4.2). 
The Mip inhibitors were not tested in B. cenocepacia due to the limited time 
available as well as the limited Mip inhibitors available.  The adherence assay results had 
no significant difference between the experimental wells and the control wells and 
therefore testing did not go ahead. Based on past literature it was observed that B. 
pseudomallei Mip did not affect adherence to epithelial cells and as B. cenocepacia and 
B. pseudomallei are in the same genus it is likely that the Mip proteins of each species 
possess similar functions. If further time was available, it would be interesting to test 
this premise as differences in bacterial counts are observed between the experimental 
wells and the control wells of the adherence assays. Particularly when testing Mip 
inhibitors in strain 165, which adhered at a higher concentration in comparison to strains 
164 and 167. (Figure 4.3).  
7.4.2 K. pneumoniae and B. cenocepacia internalisation, survival and replication 
within RAW264.7 macrophage cells with the Mip inhibitors 
Mip proteins have been demonstrated to be involved in intracellular infections of 
L. pneumophila, N. gonorrhoeae, B. pseudomallei, C. trachomatis and T. cruzi (Cianciatto 
et al. 1989; Leuzzi et al. 2005; Norville et al. 2011a; Lundemose, Kay & Pearce 1993; 
Moro et al. 1995). In these pathogens, different functions of Mip have been identified. 
For example, in L. pneumophila it appears Mip proteins are repressed directly after 
internalisation but regain full activity after 24 hours of intracellular replication (Wieland 
et al. 2002). In B. pseudomallei it is demonstrated that Mip proteins are important in 
bacterial motility, protease production, and acid tolerance and in N. gonorrhoeae it was 
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demonstrated that the presence of Mip promoted intracellular survival (Norville et al. 
2011a; Leuzzi et al. 2005). 
K. pneumoniae strains ST628 and ST14 were tested with Mip inhibitor 354 and 214 
as they were the only strains that were internalised into the macrophages (Figure 5.2). 
ST14 was the only strain that was internalised, survived and replicated in the 
macrophages during the 24 hours post-infection. Thus two time points were observed, 
a 0 hour time and a 24 hour time point. Strain ST628 did not survive during 24 hours in 
the macrophages and therefore only a 0 hour time point was observed. The results of 
these assays demonstrated that in strain ST628 a trend in decreased viable bacterial 
counts was observed with the presence of inhibitor, in comparison to the DMSO control. 
Decreased viable bacterial counts ranged between 40 - 80% with inhibitor 354 and 
between 40 - 60% with inhibitor 214, in two out of the three assays conducted (Figure 
6.3). An increase in viable bacterial counts with inhibitor was observed in the third assay, 
however, this is most likely due to introduced experimental errors. For example, maybe 
the inhibitors were not fully dissolved and had formed crystals in solution, impacting on 
the binding to Mip proteins. Based on these results it appears that Mip proteins play a 
role in internalisation of this K. pneumoniae strain and early infection in macrophage 
cells, however the exact mechanisms are not known.    
In strain ST14 no significant effect was seen with the presence of Mip inhibitors at 
both the 0 hour time point and the 24 hour time point post-infection (Figure 6.4). In fact, 
an increase in viable bacteria was observed in comparison to the DMSO control for 
inhibitor 354 at the 0 hour time point and inhibitor 214 at both time points. These results 
suggest that Mip proteins may not be involved with intracellular virulence of this strain. 
The increased viable bacterial counts observed with the inhibitors, in comparison to the 
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DMSO control is most likely attributed to high variation rather than the Mip inhibitors 
promoting virulence in this strain. 
B. cenocepacia strain 165 was tested with Mip inhibitors 354 and 214 as it was the 
only strain that was capable of replicating during 24 hours in the macrophages. Both 
strains 164 and 167 did not replicate during a 24 hour period and declined in the number 
of viable bacteria (Figure 5.3). Thus, the 0 hour time point and 24 hour time point post-
infection were examined with inhibitors in strain 165. The results demonstrated that 
inhibitor 354 had an effect at the 0 hour time point in two out of the three assays 
conducted. However, very little difference was observed between inhibitor 214 and the 
DMSO control (Figure 6.5). In B. cenocepacia flagella has been identified as an important 
mechanism of the bacteria to internalise host cells (Tomich et al. 2002). In B. 
pseudomallei the Mip knockout mutant was not able to produce flagella and had 
significantly impaired motility (Norville et al. 2011a). Therefore, even though the 
presence of flagella is unknown in strain 165, based on the results obtained it seems 
that Mip proteins may affect flagella formation in B. cenocepacia. This is because a 
decrease in viable bacterial counts were observed with inhibitor 354, in comparison to 
the DMSO control (Figure 6.5).  
At the 24 hour time point an approximate 20 - 30% decrease in viable bacterial 
counts were observed in both inhibitors in two out of the three assays conducted. 
(Figure 6.5). As mentioned above, it has been demonstrated that the L. pneumophila 
Mip is supressed directly after internalisation but regains full activity after 24 hours 
(Wieland et al. 2002). This conclusion may explain why the Mip inhibitors had an effect 
at the 24 hour time point as the B. cenocepacia Mip may function in a similar manner to 
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the L. pneumophila Mip wherein full activity is seen after 24 hours of intracellular 
replication.  
7.5 Limitations and future work 
As observed throughout all analysis, no statistically significant differences were 
found despite apparent numerical differences between the controls and experimental 
results, particularly when testing the Mip inhibitors in K. pneumoniae and B. 
cenocepacia, due to the high variability of cell based experimentation. If more time was 
available, these experiments should be repeated to increase the statistical power of the 
study. Besides possible experimental error, a reason for high variation in numeric end 
points observed in these experiments could be due to the specific concentration of 
macrophages and bacteria used in each assay. Even though a concentration of 1 x 106 
cells/mL and a bacterial dilution of 1 x 109 - 2 x 109 CFU/mL was aimed for, this count 
was difficult to achieve exactly in each assay. Care was taken to ensure consistent 
experimental conditions however changes in growth of the macrophages and bacteria 
between individual assays will increase variability of the results. 
Future work specific to this study could be to compare the effects of using different 
MOIs, changing the incubation times for shorter or longer periods and having more time 
points. A 1 hour incubation time was utilised for infection with macrophages and Mip 
inhibitor-bacteria binding time, therefore, it would be interesting to see the impact this 
has on infectivity of K. pneumoniae and B. cenocepacia with different incubation times. 
Adding more time points for the internalisation, survival and replication assays will 
provide key insight into the various stages of intracellular infection, with and without 
Mip inhibitor. Using different strains of bacteria and different cell lines will also be 
beneficial in acquiring a better understanding of the virulence of these pathogens, 
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particularly when comparing infection potential in epithelial cell lines and macrophage 
cells lines. Testing the Mip inhibitors in a range of strains will increase knowledge of 
strain variability, particularly in K. pneumoniae and cblA positive B. cenocepacia strains. 
It has been identified by some studies that B. cenocepacia can be cytotoxic as was 
observed in a cable pili positive isolate in epithelial cells (Cheung et al. 2007). Therefore, 
conducting cytotoxicity assays alongside the plate count assays will provide comparisons 
on pathogenicity of B. cenocepacia. Finally, as very little is known about the putative 
Mip proteins of K. pneumoniae and B. cenocepacia, it is evident that an extension of this 
study would be to characterise these proteins with molecular methods. For example, 
creating a Mip knockout mutant of these pathogens and comparing virulence with the 
wild-type strain.  
7.6 Conclusion 
In conclusion, this study has demonstrated that putative Mip proteins exist in K. 
pneumoniae and B. cenocepacia. They are homologous to the B. pseudomallei and L. 
pneumophila Mip, and contain highly conserved key amino acid residues of the active 
site previously identified in B. pseudomallei. Based on the results, the adherence assay 
model developed for these pathogens showed that all strains of K. pneumoniae and B. 
cenocepacia were able to adhere to the macrophages, however, the concentration at 
which they adhered varied between strains. The internalisation, survival and replication 
assay model developed for K. pneumoniae and B. cenocepacia demonstrated that in K. 
pneumoniae, not all strains were internalised into the macrophages, and only one strain 
was able to replicate intracellularly at low concentrations. In comparison, all B. 
cenocepacia strains were internalised into the macrophages, however, only one strain 
was able to replicate intracellularly. When testing the Mip inhibitors on adherence of K. 
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pneumoniae, little effect was observed with the presence of the inhibitors. However, 
when testing the Mip inhibitors on internalisation, survival and replication of K. 
pneumoniae and B. cenocepacia, trends in the data suggest that the Mip inhibitors had 
an effect on the intracellular virulence of these pathogens. Therefore from this 
preliminary study, it seems that Mip inhibitors have potential broad-spectrum activity 
in both K. pneumoniae and B. cenocepacia. In order to confirm this, characterisation of 
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